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ABSTRACT
Alicia Lynn Blaker: Regulation of Smooth Muscle-Specific Transcription by
Serum Response Factor and Formin Homology Domain Containing Protein 1
(Under the direction of Christopher P. Mack)
The regulation of vascular smooth muscle cell (SMC) differentiation is
important during vasculogenesis, angiogenesis, and cardiovascular diseases,
such as atherosclerosis and restenosis. Previous studies have shown that SMC
differentiation marker gene expression is regulated by serum response factor
(SRF) and the myocardin family of SRF co-factors (myocardin and the
myocardin-related factors, MRTF-A and MRTF-B). A major goal of the current
studies was to identify post-translational modifications of SRF that regulate SMC-
specific gene expression. By screening phosphorylation deficient and mimetic
mutations in SRF -/- ES cells, I identified T159 as a phosphorylation site that
significantly inhibits SMC-specific gene expression. In vitro and in vivo labeling
studies demonstrated that T159 was phosphorylated by protein kinase PKA, and
results from gel shift and chromatin immunoprecipitation assays demonstrated
that T159 phosphorylation inhibited SRF binding to the CArG elements present
within the promoters of the SMC-specific genes. Based upon the identification of
Ubc9 in a yeast-two-hybrid screen for SRF binding proteins, I also tested the role
of sumoylation on SRF activity. In vitro sumoylation assays identified K147 as the
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major SRF sumoylation site, but a sumoylation deficient K147R mutation had no
effect on SRF-dependent SMC-specific gene expression.
Our lab has also demonstrated that MRTF nuclear localization and activity
is regulated by changes in actin dynamics, and a second goal was to determine
whether the diaphanous formin, FHOD1, played a significant role in this process.
Using RNAi techniques I demonstrated that FHOD1 was important for SMC
differentiation marker gene expression in 10T1/2 and that over expression of a
constitutively active version of FHOD1 strongly up-regulated SMC-specific
promoter activity.  Additional studies showed that phosphorylation of FHOD1 in
the diaphanous auto-regulatory domain may contribute to FHOD1 activation and
that FHOD1-mediated actin polymerization in the nucleus may be important for
FHOD1's effects on MRTF activation.
Taken together, my results indicate that PKA-mediated phosphorylation of
SRF and FHOD1-mediated actin polymerization regulate SMC-transcription
providing two novel signaling mechanisms for the control of SMC phenotype.
Future experiments extending these findings should lead to a better
understanding of SMC's role in cardiovascular disease and to targets for treating
these conditions.
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CHAPTER I
Introduction
2Physiological role of smooth muscle cells
Smooth muscle cells (SMCs) play several important functional roles in an
organism.  SMCs stabilize and strengthen most hollow organs including the
vasculature by surrounding the epithelial/endothelial layers of these organs.
They express high levels of contractile proteins that add tensile strength and they
also secrete matrix proteins that add further structural integrity.  SMCs also
contract to regulate movement through these organs and this property is a
particularly important feature of vascular SMCs (VSMCs), which respond to
hormones and many environmental cues to regulate blood flow and pressure.
Embryonic origins of VSMCs
Embryonic vasculature patterning is a multicellular process that is initiated
by endothelial cell differentiation from angioblasts (mesodermal precursor cells),
migration and assembly into endothelial tubes, (76) and recruitment of SMCs as
the vessel matures (16).
Although VSMCs arise from many sources (reviewed in Majesky 2007)
within the embryo, including cranial neural crest, proepicardium, mesothelium,
and somites (116), we know very little about precise mechanisms that regulate
this process.  It is also important to note that although these SMC subtypes have
vastly different origins, they all express nearly identical repertoires of SMC
differentiation marker genes.
3Cranial neural crest cells
Cranial neural crest cells are derived from ectoderm and in a region near
somites 1-3 of the chick embryo they are often referred to as cardiac neural crest
due to their contributions to the heart.  As discovered by a genetic approach in
the embryonic chick-quail chimeras, cranial neural crest cells form the SMC layer
of the pharyngeal arch arteries, and some migrate further to invest the cardiac
outflow tract and septation between the aorta and pulmonary artery (93).  This
finding has been further substantiated in two murine models that employed Cre-
lox technology.  Wnt1-Cre crossed with a floxed Rosa26 (81) or protein 0-Cre
crossed with a floxed EGFP (140) resulted in reporter expression in neural crest
cells that had migrated to form vasculature.  These mouse models identified
neural crest cells as the SMC source for the ascending and arch portions of
aorta, ductus arteriosus, right subclavian artery, and right and left common
carotid artieries (81, 140).
Proepicardial organ
The SMCs that line the coronary arteries arise from the proepicardial
organ. The neural crest reporter was expressed in coronary VSMCs only within a
short distance of their aortic root, where there was a finite and abrupt boundary.
The remaining coronary arteries arise by vasculogenisis from the proepicardium.
During the looped heart stage, the proepicardial mesothelial cells respond to
cardiac signals and either form villous outgrowths (chick) or vesiculate to form
contacts with the heart.  The cells undergo epithelial-to-mesenchymal transition,
migrate into the heart, and form coronary vessels, including SMCs (31, 90, 158).
4Mesothelium
Mesothelium, mesodermal-derived cells that form a lining for organs and
the walls of the pleural and peritoneal body cavities, is also a source for VSMCs
of the mesenteric vasculature.  Mesothelial cells were identified as a source for
this vasculature by using the Wilms’ Tumor-1 transcription factor promoter in a
Cre recombinase system. As mesothelial cell markers have also been identified
in some adult aortas, the mesothelium is hypothesized to provide a source of
adult SMC precursors as needed in response to injury (210).  Not all of the
VSMCs in the abdominal cavity arise from mesothelial cells, as the splanchnic
mesoderm directly supplies SMCs for the thoracic aorta (116).
Somites
Somites are compacted whorls of mesodermal cells that become bound
together by epithelium and reside on both sides of the neural tube.  They
contribute SMCs to the dorsal aorta in the region that is caudal to the neural
crest-derived SMCs (caudal to pharyngeal arches).  Two functional components
of the somites, sclerotome and myotome, provide SMC progenitors for this region
of the dorsal aorta.  These somites express Pax3 in their final positions in the
ventral wall of the thoracic aorta juxtaposed to SM α-actin-expressing cells.
Furthermore, the Pax3-deficient mouse has a thinner ventral aorta wall than wild-
type, age-matched embryos (17, 38).  There is an additional population of cells in
the E9.5 murine dorsal aorta that may arise from the third component of somites,
the dermomyotome.  This patch of multipotential cells are mesangioblasts, which
5can travel in the blood and may serve as progenitors for blood, cartilage, bone,
smooth muscle, cardiac muscle, and skeletal muscle (26).
Adult progenitors
Adult vascular progenitor cells reside in both the tunica media and the
adventitia layers of the aorta and carotid arteries.  Pericytes, for example, are a
relatively undifferentiated, mesenchymal-like cell that can differentiate into a
fibroblast, SMC, or macrophage.  Additional sources of progenitors are adipose
tissue, cardiac progenitor cells, amniotic fluid-derived mesenchymal cells, bone
marrow-derived stromal cells, and follicular dendritic cells (reviewed in (116)).  In
the adult, existing SMCs can also be a source for new VSMCs by resuming their
synthetic, proliferative phenotype (reviewed in disease section).  Understanding
regulation of the contractile VSMC phenotype is the overarching focus of the
Mack lab and work in this thesis is in support of this goal.
Signals that regulate SMC differentiation
There are many signals that regulate SMC differentiation.  Platelet-derived
growth factor (PDGF) and transforming growth factor (TGF) are key signaling
components and are described below.  Many more exist, including sphingosine-
1-phosphate (102) and thrombin (53), although many of the VSMC responses
may be secondary to effects on endothelial cells (152)   
PDGF
During vascular development, PDGF signaling recruits VSMCs to arteries,
and in the absence of PDGF compensatory mechanisms can stimulate VSMC
6investment.  PDGF is a polypeptide released from endothelial cells (platelets or
macrophages in disease) that stimulates pericyte or SMC investment of the
vessel wall.  The PDGF (A and B) ligands and the PDGF receptors (R) (α and β)
knockout animals are all lethal at embryonic or early perinatal stages (12) (94)
(186) (187) due to varying types of microvascular hemorrhagic problems.
Although SMC investment seemed fairly normal in these mice (101) , additional
studies of PDGFRβ -/- chimeras revealed that PDGF signaling is important for
proper pericyte and SMC investment (27) .
TGFβ
TGFβ1 signaling also regulates myogenic contribution to vasculogenesis.
The TGFβ1 knockout mouse is lethal by E10.5 and cannot form stable yolk sac
vessels or perform hematopoeisis.  Although the weak vasculature was initially
identified as a potential defect of endothelial cell differentiation (32), subsequent
work has identified a role for TGFβ1 in VSMC differentiation.  As the TGFβ1
knockout mouse is lethal before VSMC investment, an embryonic stem cell
model was used in conjunction with methods to inhibit endogenous TGFβ1
activity and displayed a dependency of VSMC-specific expression on TGFβ1
signaling (184).  Additionally, a downstream signaling molecule (SMAD5) and
both TGFβ receptor types I and II have knock-out animals with irregular yolk sack
vasculature and embryo vessels with decreased VSMC investment (224) (32)
(151).
7SMCs in vascular disease
Since vascular SMCs also regulate vessel diameter and blood flow they
express a repertoire of cell type specific contractile proteins, surface receptors,
and second messenger pathways that are critical for contraction (reviewed in
(152)). Unlike skeletal and cardiac muscle cells, SMC do not undergo terminal
differentiation but retain a capacity to undergo significant and reversible changes
in phenotype in response to environmental cues.  The ability of a SMC to
modulate its phenotype was first observed by Campbell and Campbell in 1981
(14) and many of their original concepts have dictated the current direction of
vascular SMC research.  This plasticity facilitates SMC function in vascular
morphogenesis and during injury repair, as the synthetic phenotype is more
efficient in response to mitogenic stimuli.  However, SMCs in the synthetic
phenotype also have a decreased ability to metabolize low density lipoproteins,
which contributes to the vessel’s atherogenicity (14).  The synthetic SMC
phenotype facilitates its involvement in the pathogenesis of multiple human
diseases, including atherosclerosis, restenosis, hypertension, and tumor-
associated angiogenesis.  Atherosclerosis and restenosis are described briefly
below.
Atherosclerosis
During atherosclerosis some signaling pathways that may be normal
during embryonic development turn aberrant.  In response to signaling –by
factors such as PDGF-BB, interleukin-1, and tumor necrosis factor α –VSMCs
8begin to proliferate and migrate through the endothelial layers and form the
plaque or neointima.  While in this “synthetic” VSMC phenotype, the cell can
produce more collagen and may take up more lipid.  Both macrophages and
SMCs can become foam cells, which are lipid-laden cells that contribute to the
pro-inflammatory response (33).
A mouse model for atherosclerotic lesion development was generated in
1992 by Zhang et. al. (234) by making a mouse that is apolipoprotein E-deficient.
Apolipoprotein E is a protein that associates with low density cholesterol in the
plasma and is a ligand for receptors whose activation clears the cholesterol from
circulation.  Deficiency of apolipoprotein E results in a mouse model that is
spontaneously atherosclerotic (234).  Further studies, in which these mice were
fed a high-fat, Western-type diet, resulted in mice with more advanced lesions, in
a spectrum similar to those observed in humans.  These lesions included
monocyte attachment to endothelial cells, macrophage infiltration and
investment, foam cell lesions and fatty streaks, and fibrous plaque formation that
includes SMC recruitment to the cap (141).
VSMCs play an important role in atherosclerotic plaque formation.
Platelets and lesion macrophages that are attracted to the site of injury produce
PDGF, which is a potent stimulator of SMC proliferation and migration (86).
SMCs produce matrix metalloproteinases, which degrade and remodel the
extracellular matrix, making it easier for SMC migration (42).  However, when the
VSMCs have migrated into the plaque, TGFβ may contribute to the stability of the
plaque.  Apolipoprotein E-deficient mice with atherosclerotic lesions were treated
9with a soluble TGFβ receptor II protein that inhibits TGFβ signaling.  The plaques
in these animals had decreased matrix production and more frequent interplaque
hemorrhages. This supports a role for TGFβ-induced SMC function in vascular
repair, including matrix production (106). There is an important balance between
repairing the vasculature and contributing to the problem.
Restenosis
One of the prominent treatments used to help restore blood flow to
narrowing arteries is balloon angioplasty, which although sometimes necessary,
can itself induce additional arterial injury.  Restenosis results from balloon
overstretch, which injures or even tears the internal elastic lamina and tunica
media.  This results in a loss of contractile phenotype of the tunica media and
exposure of the subendothelial matrix.  Circulating blood, activating platelets, and
thrombogenic factors stimulate VSMC function (232).   For example, PDGF-BB
can induce disassembly of stress fibers and migration of these cells to the intima
(11).  The intima then begins to thicken due to VSMC proliferation and migration
into the area as well as their excessive contribution of extracellular matrix (232).   
Thus, the newly thickened intima, or neointima, narrows the lumen of the artery.
Research for new treatments
Although stem cell use in medicine has been a source of controversy, the
feasibility and potential benefits are mounting.  In an effort to stimulate
expression of cardiac mRNA and protein expression in pluripotent stem cells,
Sadek et. al. screened a chemical library for activators of the cardiac-specific
cofactor, Nkx2.5 (171).  They identified a family of small molecules, the
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sulfonylhydrazones, whose presence stimulated expression of cardiac genes in
stem cells.  These stem cells were later grafted into a mouse cryoinjury model
and improved cardiac function compared to control grafts (171).  A similar
experiment using mesenchymal stem cells was performed; this time achieving an
increase in cardiac differentiation by forced expression of the cardiac cofactor,
myocardin (described in later section).  Injury was induced by left anterior
descending coronary artery ligation.  After myocardial infarction, treated stem
cells were injected into the injured area.  Forced myocardin expression improved
left ventricular function, engraftment, and induction of the cardiomyocyte-like
phenotype.  Of course, long-term viability of the engraftment and forced
myocardin expression has not yet been studied (51). However, regulation of
myogenic differentiation contributed the groundwork for such a treatment.
Similarly, the regulation of SMC differentiation and phenotype is important
for treatment of arteriosclerosis.  For example, in organ transplants vascular
stenosis can occur in vessels of a donor organ, which is referred to as transplant
arteriosclerosis.  Stem cells (from bone marrow and non-bone marrow tissues)
derived from the recipient may repair damaged endothelial cells and VSMCs that
have died in the donor vessels.  Controversy surrounds circulating stem cell
vascular repair and the hypothesis that these cells may contribute to neointimal
lesions of the vessel wall (218).  Clearly, more research is necessary before stem
cells will be of clinical use.  Phenotypic switching of VSMCs is controlled at the
level of gene expression.  To make full use of potential stem cell contributions we
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must first elucidate the mechanisms that govern the role of VSMCs in
development and disease.
Regulation of SMC differentiation by SRF
SMC are defined by the expression of multiple marker genes including SM
myosin heavy chain (SM MHC), SM α-actin, SM 22α, telokin, and calponin. A
transcription factor that specifies SMC lineage or completely explains SMC-
specific transcription has not yet been described, but extensive evidence from
our lab and others has shown that the transcription factor, serum response factor
(SRF), is a major regulator of SMC differentiation marker gene expression. SRF
binds to CC(A/T)6GG (“CArG”) cis elements that are present in the promoters of
nearly all of the SMC-specific marker genes (64, 96, 109, 111, 113, 130).  The
CArGs within any given SMC-specific promoter are nearly completely conserved
between species, and multiple CArGs have been shown to be required for the
high level of activity that these promoters exhibit in SMC cultures and in
transgenic mice (64, 84, 96, 109, 113, 118, 130, 137, 226).  There are VSMC-
specific genes that are not CArG-dependent, including the ACLP promoter (117).
SM α-actin and other SM-specific genes are also regulated by a combination of
transcription factors with their own binding sites in the promoters (88).
SRF was initially identified in 1987 as a nuclear protein that binds to the
cfos serum response element (SRE) (195).  The SRE is an element in the cfos
promoter that is 5’ to the transcription start site that is required for serum-induced
expression of cfos.  The SRE is a short sequence of dyad symmetry, which
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refers to the sequence found in the cfos promoter and has since been found to
include a CArG element (46, 52, 196).
SRF functional domains
SRF binds the CArG element through its MADS box domain (See Figure
1.1).  The MADS box is a DNA binding motif that is conserved throughout yeasts,
plants, insects, amphibians, and mammals.  The domain is named for the original
four members of the family: MCM1, Agamous, Deficiens, and SRF  (reviewed in
(182)).  The human SRF MADS domain crystal structure has been solved in
complex with the cfos SRE and with the SRF cofactor SAP-1 (155) (57) (136).
The first three dimensional structure of SRF was reported in 1995 by Pellegrini
et. al.  The core secondary structures are an αI helix from amino acid 153-179, a
βI sheet from amino acid 182-188, a βII sheet from amino acid 194-198, and an
αII helix from amino acid 209-219.  SRF functions as a homodimer and it is the
antiparallel, amphipathic αI helices from the two proteins that form the primary
contacts with the DNA.  The αI helices fit in the minor groove of the DNA, which
is composed of the CArG box.  The αI helices induce a bend in the DNA that
increases the interactions and allows the N-termini of the helices to contact the
DNA major groove.  Next to the helices, the β-sheets form an antiparallel layer
and provide the major site of dimerization.  Finally, the αII helices lay on top of
the β-sheets (155).  The MADS structure results in a domain that binds DNA,
homodimerizes, and interacts with cofactors.
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Outside of the MADS box, SRF has two other significant functional
domains.  Slightly N-terminal to the MADS box, there is a nuclear localization
signal and the majority of the C-terminus is a transactivation domain, thus
defining  SRF  as  a  nuclear  protein  and  a  transcription  factor.  The  nuclear
localization signal was identified in 1995 by Gauthier-Rouviere et. al. and
includes arginines 95, 96, and 100 and lysine 99 (45).   The transactivation
domain was confirmed by making an SRF-GAL fusion protein that mapped the
required SRF amino acids to 339-508, which were sufficient to stimulate
transcription (82).
SRF -/- mouse
As SRF is a ubiquitously expressed transcription factor, elimination results
in severe gastrulation defects.  The defects appear shortly after the onset of
gastrulation (mouse E7.0), suggesting that SRF is not required for proliferation
up to E6.5.  Then, the ectoderm and endoderm layers misfold and there is a lack
of construction of the entire mesoderm.  Thus, SRF is required for induction of
the mesoderm.  The primitive streak does not form in these mice and the
disintegrating embryos are lethal by E12.5 (6).
Although SRF null mice do not survive, SRF knockout embryonic stem
cells (SRF -/- ES cells) were established (208) and have proven a useful system
in which to study SRF-dependent transcription.  Philippar et. al. have stimulated
differentiation in ES cells for only 8 days and induced cardiac- and VSMC-
specific expression.  Under monolayer conditions, removing Leukemia Inhibitory
Factor and adding retinoic acid resulted in a peak of cardiac- and VSMC-specific
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expression by 4 days of differentiation (161). These cells do not express cardiac-,
skeletal-, or VSMC-specific marker genes, including skeletal, cardiac, or VSM
actin, Bmp2, or T(Bra) (mesodermal marker) without SRF rescue (208).
However, although SRF is required for expression of immediate early genes and
participates in cell cycle progression, the SRF-/- ES cells do not have any
difficulty proliferating (175).  Therefore, these cells are a useful experimental tool
and have been used in many studies located in the second and third chapters of
this thesis.
SRF has also been implicated in SMC differentiation marker gene
expression by dominant negative approaches and SRF -/- ES cells.  Although
SRF is expressed highly in SMC it is a ubiquitously expressed transcription factor
that also regulates other CArG-dependent genes including the early response
growth factor, c-fos, and several cardiac and skeletal muscle markers. This
suggests that regulation of SMC-specific transcription by SRF requires additional
regulatory mechanisms.  As the SRF null mouse dies before the differentiation of
myogenic cells, a cardiovascular-specific SM22α-Cre mouse was created to
determine whether SRF was important for cardiovascular development and
function.  The decrease in SRF expression in cardiomyocytes and VSMCs
resulted in lethality at E11.5. The VSMC defects contributing to lethality were
altered recruitment of SMCs to the dorsal aorta and improper assembly of
contractile elements (132).  SRF is also required in cardiac development.  Two
separate cardiac-specific ablations of SRF (α  or β MHC-Cre transgenic mouse
lines crossed with lox P SRF) resulted in embryonic lethality during chamber
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maturation (145, 154).  Cardiovascular development and VSMC investment of
the vasculature is required for survival and these processes require SRF.
Control of SRF activity
Several mechanisms are likely to be involved in the control of SMC-
specific transcription by SRF. First, while the consensus c-fos CArG element is a
high affinity SRF binding site there is considerable heterogeneity between the
CArG elements found in the SMC promoters and many do not conform to this
consensus. These differences dramatically lower SRF binding affinity and are
very important for promoter specificity and overall promoter activity in SMC (59)
(114, 180).  For example, when the low affinity CArG B element within the SM α-
actin gene was replaced with the high affinity SRE CArG, promoter activity was
significantly enhanced, was less responsive to angiotensin II-induced up-
regulation, and was no longer limited to SMC (59). The importance of this
mechanism is further illustrated by several studies that have shown that SRF
binding to CArG elements is regulated (both positively and negatively) by a
number of homeobox proteins including Prx1, Barx2, and HOP (60, 63, 181,
228).  Second, all three muscle cell types express significantly higher levels of
SRF than non muscle cell-types which is likely to favor SRF binding to the low
affinity muscle-specific CArG elements in these cells. Third, SRF has been
shown to interact with a variety of other transcription factors that can confer both
gene- and cell-type-specificity. The first SRF co-factors identified, the ternary
complex factors (TCFs), Elk-1, Sap-1, SAP-2/NET/ERP, are ubiquitously
expressed and regulate early response gene expression and cell growth. When
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activated by MAP-kinase-dependent phosphorylation, the TCFs interact with SRF
at the serum response element to form a ternary complex.  This complex is
stabilized by protein-protein interactions between TCF and SRF but also by
protein–DNA interactions between TCF and the Ets domain just upstream of the
CArG element (28, 67, 122).  SRF has also been shown to interact physically
with GATA-4 and Nkx2.5 to regulate cardiac-specific gene expression and MyoD
and myogenin to regulate skeletal muscle-specific gene expression (19, 20, 54,
177). The SMC-specific LIM domain proteins, CRP1 and CRP2, also bind SRF
and may facilitate SRF’s interactions with other factors by acting as adapter
molecules (18).
The myocardin family of SRF cofactors
Myocardin
Arguably the most important mechanism for regulation of SMC
differentiation by SRF involves its interaction with the SRF cofactor, myocardin.
Myocardin was identified in 2001 and was subsequently shown to powerfully
stimulate several CArG-containing muscle-specific genes by binding to SRF.
Initial northern analyses in adult mouse tissues demonstrated that myocardin
was specifically expressed in the heart, but subsequent studies using in situ
techniques showed that it was also expressed in most SMC with particularly
strong expression during early SMC development (34, 200, 201).  Several groups
used dominant-negative myocardin variants and siRNA approaches to
demonstrate that myocardin was required for SMC differentiation marker gene
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expression in primary rat aortic SMC, and in A7r5, Pac1 and A10 SMC lines (34,
203, 229).  Deletion of myocardin in the mouse resulted in a hemorrhagic
phenotype and embryonic lethality at E10.5.  The authors did not find SMC
differentiation and therefore associate hemorrhaging with a lack of SMC
investment of the vasculature (99).  Myocardin has been further shown to
regulate expression of contractile genes in a neural-crest-specific myocardin
knockout.  A Wnt1-Cre mouse was employed to specifically knock out myocardin
in SMCs that arise from the neural crest.  These SMCs expressed the SMC
synthetic phenotypic profile rather than the SMC contractile-specific marker
genes.  Additionally, the ductus arteriosis, which is populated by neural crest-
derived SMCs, requires contraction of the SMCs in order to close properly.  The
diminished expression of contractile proteins in the myocardin-deficient embryos
coincides with a lack of ductus arteriosis closure.  It is also significant to note that
the myocardin-deficient neural crest stem cells did migrate to the appropriate
field, and then failed to express the required contractile proteins (74).  SRF
knockdown by short hairpin RNA impairs contractile expression in SMCs. This
phenotype is rescued by over-expression of myocardin (105).  This may be
explained as the residual amount of SRF that is present is sufficient when paired
with the transcription-stabilizing capabilities of myocardin.  (See EMSA data in
phosphorylation chapter).
MRTF-A and MRTF-B
Two Myocardin-Related Transcription Factors, MRTF-A and MRTF-B,
have also been identified that have similar transcriptional activities to myocardin
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but are expressed more widely. The myocardin factors share homology in many
domains (see Figure 1.2): the basic domain is for nuclear localization, the Q-rich
domain binds SRF, transactivation domain is for transcription, the SAP domain
indicates chromatin remodeling, and the RPEL motifs interact with RhoA
(discussed in RhoA section).  We and others have recently shown that the
MRTFs are also important regulators of SMC differentiation in at least some SMC
subsets and may be important for the activation of SMC-specific transcription by
extrinsic factors (103, 108).
The MRTF-A knockout mouse was created by two groups simultaneously,
both defining the key developmental deficiency in the mammary gland
myoepithelium.  Although the animals are viable and develop normally otherwise,
the affected cells prevent mothers from efficiently feeding young of any genotype.
Sectioning and staining of the mammary glands revealed an increase in fat tissue
and a decrease in epithelial tissue in the MRTF-A -/- mothers. Although it is
somewhat surprising that VSMCs in these animals were not otherwise impaired,
there is some redundancy in myocardin family members and the affected
myoepithelial cells are at least similar in contractile function to the VSMC (193)
(97).
The MRTF-B knockout mouse was also simultaneously established by two
groups in 2005.  Both groups determined that functionally null MRTF-B mice
were lethal between E17.5 and postnatal day 1.  Combined efforts have found
defects in the cardiac outflow tract, aortic arch arteries, branchial arch arteries,
and ventricular septum.  Also, mice had a double-outlet right ventricle (pulmonary
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and aorta arise from the right ventricle instead of only the pulmonary artery), a
thin-walled myocardium, and failure of SMCs to differentiate within
aorticopulmonary septum and the branchial arch arteries.  These cardiovascular
components arise from the neural crest progenitors, and define a role for
MRTF-B in neural crest cell differentiation (95, 148).  The functional variation for
myocardin, MRTF-A, and MRTF-B in VSMC differentiation is due, at least in part,
to their localization differences, which will be expressed in a RhoA section.
Regulation of SRF activity by phosphorylation
SRF is a phosphoprotein that has been shown to be phosphorylated in
vitro by several kinases including casein kinase II, CaM kinase IV, and MAPKAP
kinase 2. However, in many instances the consequences of SRF phosphorylation
by these kinases was unclear. For example, in early studies on the regulation of
c-fos, it was shown that N-terminal serine/threonine phosphorylation at a number
of sites near the DNA binding MADS domain (especially S103) increased SRF
affinity for the SRE CArG element in gel shift assays. However, these changes
had only marginal effects on SRF’s ability to stimulate c-fos expression and it
was subsequently shown that SRF phosphorylation was not changed following
serum stimulation suggesting that SRF phosphorylation may not directly regulate
c-fos expression under these conditions. Two more recent studies have
demonstrated that SRF phosphorylation may be important for regulating cardiac-
specific transcription. In one study SRF T159 was shown to be phosphorylated
by myotonic dystrophy protein kinase (DMPK) in a cardiac cell line, and this
phosphorylation was shown to be important for regulating cardiac α-actin
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promoter activity. This effect was not mediated by increased SRF binding, but
was possibly caused by increased association of SRF with GATA-4 and Nkx2.5
(78).  Data in chapter II describe a role for T159 phosphorylation by PKA in
VSMC-specific promoter activation.  A very recent study by Iyer et al. showed
that SRF was phosphorylated in ES cells by PKC-α and that this event inhibited
SRF-dependent activation of the cardiac actin promoter, but did not affect
regulation of c-fos.  Importantly, none of these studies were performed in SMC
and very few examined the effects of SRF phosphorylation on cell-type-specific
gene expression making it very difficult to extrapolate these results in regard to
the regulation of SMC-specific transcription by SRF phosphorylation. One study
did show that arginine vasopressin (AVP) modestly increased SRF
phosphorylation at S103, but it was unclear whether this phosphorylation was
directly responsible for the AVP-induced increase in SM α-actin promoter activity
observed in this study (43).  The schematic in figure 1.1 shows the location of
known and putative sites of SRF post-translational modification.  The focus of
chapter II is to characterize a role for phosphorylation of T159 by PKA in the
regulation of SRF-dependent gene transcription.  Previous research identifying a
role for PKA in SMC phenotypic modulation will be described in chapter II as well
as in “Conclusions and Future Directions” in chapter V.
Convergence of signals
It is clear that local environmental cues including integrin-matrix
interactions, cell-cell interactions, mechanical stretch, contractile agonists, growth
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factors, cytokines, atherogenic factors, and reactive oxygen species regulate
SMC differentiation (reviewed in (152)).  However the signaling mechanisms by
which these diverse pathways regulate SMC phenotype are not very clear.
Further complicating our understanding of these signaling processes is the fact
that many of the environmental factors that stimulate SMC differentiation also
stimulate SMC proliferation. While early studies suggested that growth state was
a critical determinant of SMC differentiation, it is now clear that these processes
can be dissociated (8, 25, 35, 50, 77, 147).  Since SRF regulates both, there is
likely to be an important convergence point in the regulation of SMC growth and
differentiation. An important observation in this regard, is that myocardin and Elk-
1 compete for binding to the same SRF domain within the MADS box, and that
activation of MAP-kinase signaling by PDGF-BB could increase Elk-1-SRF
association at the expense of myocardin-SRF association (205).
Although PDGF signaling is an important component regulating vascular
investment with SMCs and it is required for migration of cultured VSMCs, it also
suppresses expression of VSMC contractile marker proteins.  In cultured VSMCs
it was shown that PDGF-BB decreases myocardin, MRTF-A, and MRTF-B’s
interaction with CArG-containing SMC-specific promoters by: 1) competition of
phospho-Elk1 for SRF binding at early timepoints (.5hr post-treatment), 2)
reduction of acetylated histone H4 in these promoter regions (24hr post-
treatment), and 3) decreasing myocardin expression but not MRTF-A or MRTF-B
expression (227).  Signaling of PDGF-BB activates Erk1/2, which exerts its
kinase activity on both Elk1 and HDACs (236).  Additionally, Elk1 interacts with
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HDAC2 (223), which may explain the secondary HDAC response and the
achievement of the migratory and proliferative phenotype of the SMC.
Other signaling pathways, including focal adhesion kinase and basic
fibroblast growth factor, manage PDGF-BB-induced migration of VSMCs.
Activation of the PDGFβ receptor stimulates the ERK/MAPK pathway, which is
mediated by focal adhesion kinase.  Co-expression of a dominant negative
version of focal adhesion kinase results in a significant inhibition of PDGF-BB-
dependent migration (58).  Additionally, the basic fibroblast growth factor can
also regulate the migratory response of VSMCs exposed to PDGF-BB.  When rat
aortic VSMCs are exposed to both molecules simultaneously, basic fibroblast
growth factor dose-dependently inhibits VSMC migration towards the PDGF-BB
signal (39).
The TGFβ response is mediated by SMAD proteins, which homo- or
hetero-dimerize to relay signals from activated receptors to the nucleus.  SMAD3
activates both SM22 (165) and SM α-actin (73) expression through interactions
with the SMAD binding element in the SM promoter DNA and direct interaction
with SRF.   SMAD4 can also function synergistically with SMAD3, however, there
are some SMADs that are negative regulators of TGFβ-induced SMC-specific
expression.  SMAD6 and 7 bind to TGFβR to block SMAD 2/3 phosphorylation
and the SMAD4 synergistic function (178). These data have shown that the
SMAD proteins are mediators of the TGFβ-SMC response.
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Regulation of SMC differentiation by RhoA signaling
Another important signaling molecule that regulates VSMC differentiation
is RhoA (110, 213).  RhoA, Rac, and Cdc42 make up a sub-family of small
GTPases that regulate actin polymerization within cells.  Rho activation induces
stress fiber formation, Rac activation induces cortical actin polymerization during
lamellipodia formation, and Cdc42 activation stimulates linear actin
polymerization at the extreme cell periphery that results in filopodia formation
(56).  All GTPases cycle between an active, GTP-bound state and an inactive,
GDP-bound state.  Guanine nucleotide exchange factors (GEFs) increase the
activated state by facilitating the exchange of GDP for GTP.  GTPase activating
proteins (GAPs) increase the rate of GTP hydrolysis, facilitating the formation of
the inactive, GDP-bound state (see (213) for review) (168). In the vasculature,
RhoA can be activated by thrombin (176), angiotensin II (41), lysophosphatidic
acid (from oxidized LDL) (183), sphingosine-1-phosphate (217) endothelin-1
(220), cell adhesion molecules (13, 30), mechanical stretch (146), and shear
stress (98, 211).
The Treisman lab was the first to identify SRF as a nuclear target of RhoA
(68).  Since this finding the same lab clarified that one of the many RhoA-
controlled processes, actin polymerization, is a key participant in the regulation of
SRF.  LIM kinase activity coincided with an increase in SRF-dependent
transcription.  In this model, LIM kinase phosphorylates cofilin, thereby
inactivating it.  Since cofilin normally depolymerizes actin, this phosphorylation
event results in an increase in filamentous actin and a decrease of globular actin.
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These experiments concluded that depletion of the globular actin pool due to its
polymerization stimulates SRF activity (188).
Mack et. al. were the first to show that signaling through RhoA was
required for the SMC-specific promoters, SM22 and SM α-actin (110), and as
mention above, our studies and others have implicated the MRTFs in this
regulatory mechanism (103, 133).   Expression of myocardin, MRTF-A, or MRTF-
B in 10T1/2 cells (SM precursor cell line) results in a respective 200-fold, 100-
fold, or 50-fold increase in SM22 promoter activity (69).  This corresponds
directly with their nuclear localization patterns.  In normal culturing conditions,
myocardin is in the nucleus, MRTF-A is nuclear, cytoplasmic, or diffuse (133) and
MRTF-B is in the cytoplasm (89).  However, upon serum starvation and then
addition of 10% serum or RhoA agonists (ex. sphingosine-1-phosphate), both
MRTF-A and MRTF-B also become mostly nuclear (69, 103).  One of the
conserved domains between the mycoardin family members is the RPEL
domain, which is the region that interacts with globular actin and retains the
cofactor in the cytoplasm (163).  Mutations in this region change the localization
patterns of the myocardin family members (69), indicating that the variability in
this domain affects the translocation capabilities of the cofactors (55, 69).
However, nuclear export rather than import of MRTF-A may be the major
regulatory step in serum-induced nuclear accumulation of MRTF-A.  An elegant
set of experiments by Vartiainen et. al. have shown that MRTF-A binds globular
actin in the nucleus and disruption of this interaction is required for MRTF-A-
dependent increases in SRF-specific transcription.  Although serum stimulation
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results in nuclear accumulation of MRTF-A, this can be achieved much faster by
treating with a nuclear export inhibitor, leptomycin B.  This data implies that
MRTF-A localization may be more regulated by export than import.  In
experiments measuring fluorescence energy transfer, MRTF-A that was forced to
the nucleus (by heterogenous NLS chimera), where it interacted strongly with
actin.  The interaction was inhibited by the stimulation of actin polymerization
(cytochalasin D or serum stimulation).  Upon stimulation, MRTF-A and actin
decrease binding and MRTF-A stimulates SRF-specific transcription.  In
summary, inhibition of nuclear export is not sufficient to stimulate MRTF-A and
SRF-specific transcription, as the regulation appears to lie within its interaction
with actin monomers.  Although there is no data showing MRTF-A-bound actin
leaving the nucleus, shuttling of an actin-binding protein may provide
communication between cytoplasmic and nuclear globular actin pools (198).
RhoA regulates actin polymerization by binding to a variety of effector
proteins, including LIM kinase, Rho kinase (ROCK), myosin light chain (MLC)
phosphatase, and the diaphanous formin proteins (discussed in following
section) (115).  ROCK stimulates RhoA-dependent actin polymerization by many
mechanisms: 1) activating LIM kinases, which inactivate the actin depolymerizing
factor cofilin (5), 2) activating profilin, which binds actin and stimulates ADP/ATP
exchange in a mechanism that stimulates actin polymerization (5, 48, 144, 153).
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Formin homology domain-containing proteins
The diaphanous-related formins (DRFs), are potent actin and microtubule
polymerizing factors that are activated by the small GTPases (RhoA, Rac,
Cdc42).  These proteins have been shown to and regulate a variety of cell
processes such as migration and division (66), but data from our lab suggests
that they may also regulate SMC-specific gene expression.
Formin proteins contain the GTPase binding domain (GBD), formin
homology domain one (FH1), and formin homology domain two (FH2).  The
formin proteins have individualized specificity for Rho GTPases, which results in
individualized function.  The Dia GTPase binding domain (GBD) binds Rho-GTP,
and activates the actin nucleating capabilities of the FH2 domain (169). The FH2
and FH1 domains have specific functions; the FH2 domain binds actin filament
barbed ends to participate in the stabilization of actin polymerization and the FH1
domain contributes by interacting with an actin monomer-binding protein, profilin
(66).   
Dia1, Dia2, and FHOD1 (all DRF family members) appear to have similar
regulatory mechanisms.  The mDia1 crystal structure of the diaphanous
autoinhibitory domain (DAD) has been solved in complex with the N-terminal
regulatory region, termed the DID (also known as the FH3 domain).  The mDia1
DAD domain forms an amphipathic helix that binds a concave sequence
(MDXLLXL) in the DID domain and holds the protein in an inactive conformation
(142).  A string of basic residues (RRKR) C-terminal to the DAD also seems to
contribute to the DAD interaction with the DID (199).  The DID and DAD
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interaction can be challenged through modifications and through functions of
neighboring domains.  One of these mechanisms is interaction of the GBD
domain with activated Rho.  As reported by both Nezami et al 2006 and Rose et
al 1995 in their Dia1 crystallization, binding of GTP-bound Rho to the GBD
domain releases the autoinhibitory DAD from the DID domain (142, 169).
In Staus et. al. 2007, we published that activation of mDia1 and mDia2
stimulate VMSC-specific promoters by increasing nuclear localization and
activation of MRTF-A and MRTF-B(189).  This process was enhanced by
constitutively active RhoA and it was dependent on actin polymerization.
Furthermore, SM-specific transcription was inhibited by expressing a dominant-
negative Dia1 (189).  Given these results, we hypothesized that mDia1 and its
family member mDia2 regulate VSMC-specific promoters.
Regulation of DRFs by DAD phosphorylation
Staus et. al. have determined that phosphorylation of mDia2 in the
Diaphanous Autoregulatory (DAD) Domain enhances its activation of SM-specific
gene expression (190).  Using GST-pulldown assays, Staus et. al. determined
that the mDia2 DAD domain binds the Diaphanous Inhibitory Domain (DID) and
this interaction can be attenuated by phosphorylation in the DAD domain at both
T1061 and S1070 by Rho kinase (ROCK).  The T1061/S1070E variant also
increased nuclear localization of MRTF-B.  The mDia2 T1061 and S1070
phosphorylation sites in mDia2’s DAD are conserved in FHOD1 (190).  Basic
residues in the FHOD1 DAD domain have been identified, as phosphorylation
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targets for ROCK and PKG and activity of stimulated FHOD1 will present an
interesting area of future research (detailed in chapter IV) (194, 204).
mDia2 localization
Nuclear monomeric actin plays a somewhat undefined role in the
regulation of MRTF activity.  MRTF must be in the nucleus to increase promoter
activation of SRF-dependent transcription, but it also must not be bound to actin
(198).  Thus we hypothesize that DRFs in the nucleus regulate actin
polymerization in a mechanism that promotes nuclear retention of the MRTFs as
well as activation of SRF-dependent transcription.
Another mode of mDia2 regulation is its localization, as shown by Staus
et. al. (191).  mDia2 is localized to the nucleus upon treatment with the Crm1-
dependent nuclear export inhibitor, leptomycin B.  Truncation mutants were used
to identify two basic nuclear localization sequences.  Mutation of these basic
residues resulted in a decrease in mDia2-dependent MRTF nuclear localization
and SM-specific gene expression.  Identification and mutation of a typical Crm1-
dependent leucine-rich nuclear export signal (NES) increased mDia2 nuclear
localization and MRTF nuclear localization. Finally, treatment with PDGF-BB
resulted in a loss of nuclear mDia2 localization and its effects on SM-specific
promoter activity.  The effects of PDGF-BB could be reversed if the coexpression
of mDia2 was using a variant with a mutated NES (191).
There is conservation between the two basic regions near the mDia2 NLS
the c-terminus of FHOD1.  However, if FHOD1 contains an NES it is not Crm1-
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dependent. There is no homologous leucine-rich domain and it does not respond
to the Crm1 inhibitor leptomycin B.
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Thesis summary
It is well established that the VSMC phenotype is regulated by a complex
array of local environmental cues including growth factors, contractile agonists,
cell-cell and cell-matrix interactions, inflammatory stimuli, and mechanical
stresses.  However, the mechanisms by which these diverse signals are
integrated to regulate the SMC phenotype and the transcription mechanisms that
ultimately regulate SMC differentiation are largely unknown. SMCs require a
dynamic equilibrium of SMC-specific versus proliferative gene expression profiles
and the regulation of this equilibrium is a key component in the participation of
VSMCs in injured vessel repair and disease.  Therefore, the focus of this thesis
was identifying a dynamic regulatory event in SRF that could mediate this
transition.
There are four chapters remaining in this thesis in which I will describe my
contribution to the understanding of this field.  In chapter II, “PKA-Dependent
Phosphorylation of Serum Response Factor Inhibits Smooth Muscle-Specific
Gene Expression,” I have identified a key phosphorylation site in the MADS
domain, T159, that inhibits SMC-specific expression, while still allowing
expression of c-fos.  This phosphorylation event is stimulated by cAMP-
dependent protein kinase (PKA), which is a known regulator of SMC-specific
gene expression.  In chapter III, “Potential Regulation of SRF-Dependent Gene
Expression by SRF Sumoylation,” I explored sumoylation of SRF as a post-
translational modification that could regulate its activity.  This work began with
identification of a sumoylating enzyme in an SRF binding assay.  Although the
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interaction was confirmed and sumoylation of SRF was identified in vitro, the
event was not recapitulated in cells overexpressing SUMO1, and no functional
consequence of SUMO-defective SRF mutants was identified.  In chapter IV,
“FHOD1 Regulates VSMC-Specific Gene Expression,” I have identified a role for
the diaphanous related formin, formin-homology-domain-containing protein 1
(FHOD1).  Although FHOD1 is not the first DRF to have a role in VSMC-specific
gene regulation (189), work showing its importance in VSMCs is novel.  Finally,
in chapter V, “Conclusions and Future Directions,” I will discuss the important
findings in each chapter as well as the next unanswered questions.
CHAPTER II
PKA-Dependent Phosphorylation of Serum Response Factor Inhibits
Smooth Muscle-Specific Gene Expression
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Introduction
Smooth muscle cells (SMC) phenotypic modulation plays an important
role in the progression of several prominent cardiovascular diseases, including
atherosclerosis, hypertension, and restenosis (170).  While it is well known that
this process is controlled by local environmental cues (see (152) for review), the
precise signaling mechanisms that regulate this process are unclear. Extensive
evidence indicates that serum response factor (SRF), is a critical transcriptional
regulator of SMC differentiation maker gene expression (64, 96, 109, 111, 113,
130). However, because SRF is a ubiquitously expressed gene that also
regulates early response and cardiac- and skeletal muscle-specific gene
expression (see (131) for review), it is clear that additional mechanisms are
involved.
The identification of the myocardin family of transcription factors
(myocardin and the Myocardin-Related-Transcription Factors, MRTF-A and
MRTF-B) was a particularly important advance because these SRF co-factors
strongly transactivate SMC-specific gene expression and are required for SMC
differentiation marker gene expression in vivo (see (162) for review). Early
studies also demonstrated that SRF is phosphorylated at multiple residues just
N-terminal to the DNA binding domain by several kinases including casein kinase
II, CaM kinase IV, and MAPKAP kinase 2 (45, 62, 80, 119, 123, 134, 164).
Phosphorylation of these sites (especially Ser 103) increased SRF affinity for the
c-fos CArG. However, because SRF phosphorylation had only marginal effects
on SRF’s ability to stimulate c-fos expression and because SRF phosphorylation
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was not altered by serum stimulation (120), the physiologic significance of these
findings was unclear.
More recent studies suggest that SRF phosphorylation may regulate
differentiation marker gene expression in the heart and SMC. Iyer et.al
demonstrated that SRF was phosphorylated at S162 by PKC-α and that this
modification attenuated SRF-dependent cardiac and SM α-actin promoter activity
by inhibiting SRF binding to CArG elements (79).  Interestingly, SRF binding to
the c-fos CArG was not significantly affected by this mechanism because of the
stabilizing effects of Elk-1 within the ternary complex. This same group also
demonstrated that phosphorylation of SRF at T159, perhaps by myotonic
dystrophy protein kinase (DMPK), increased cardiac α-actin promoter activity in
CV1 cells (78).
To better examine the role of SRF phosphorylation on SMC differentiation
marker gene expression we have screened a variety of SRF phosphorylation
mutants in an SRF -/- ES cell model of SMC differentiation. Our results suggest
that SRF is phosphorylated at T159 by cAMP-dependent kinase (PKA), and that
this phosphorylation inhibits SMC-specific transcription by inhibiting SRF binding
to CArG elements.
Materials and Methods
Plasmids and SRF mutations
SRF mutations (see figure 2.1) were generated using the QuikChange
mutagenesis kit (Stratagene) or sequence overlap extension. All SRF constructs
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were subcloned into flag-tagged pcDNA3.1 for mammalian expression or pGEX-
4T1 (Amersham) for the generation of GST-fusions. Please see supplemental
methods for more detailed protocols.
Cell culture, transfections, and promoter assays
The SRF -/- embryonic stem cells were a generous gift from Alfred
Nordheim; (Tubingen University, Germany) and their culture and differentiation
have been previously described (161, 175, 208). SM α-actin and SM22 message
levels were measured by quantitative RT-PCR from RNA isolated at day 0, 3,
and 6 of the differentiation protocol. The primary rat aortic SMC cell cultures,
transient transfections, and promoter luciferase assays have been previously
described (103). Statistical comparisons between groups were made using the 2-
tailed Student's t test with statistical significance accepted at p<0.05.
Gel shift analyses
Flag-tagged SRF and myocardin factors were translated in vitro using the
TnT kit (Promega).  Binding reactions contained 1µL SRF, 2µL of myocardin
factor, 20,000 cpms of 32P-labeled oligonucleotide probe, and 0.20µg dIdC in
binding buffer (10mM Tris, pH 7.5, 50mM NaCl, 100mM KCl, 1mM DTT, 1mM
EDTA, 5% glycerol). For supershifts, 1µl of anti-flag antibody (Sigma) was added
after the first 20 min of incubation.
Phosphorylation assays
GST-SRF fusion proteins were purified from BL21 bacterial lysates using
glutathione sepharose (Amersham Biosciences). For in vitro kinase reactions
0.08 µg of purified constitutively active PKA (New England BioLabs) or 8-pCPT-
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cGMP-stimulated PKG-Iα (Promega) was incubated with 2µg GST-SRF in 25µL
kinase buffer (50mM Tris, 10mM MgCl2, 200µM ATP, and 10µCi γ32P-ATP). For
in vivo labeling, full length Wt or T159A flag-tagged SRF variants were expressed
in Cos-7 cells. Following washing in phosphate-free media, cells were incubated
with 1mCi ortho 32P for 2h and then treated with 20µM forskolin for 2.5h or
100µM 8-pCPT-cGMP. SRF was immunoprecipitated from RIPA lysates using
anti-flag agarose beads (Sigma). Phosphorylation assays in SMC were mostly
similar except that endogenous SRF was immunoprecipiatated using an anti-
SRF Ab (Santa Cruz).
Chromatin immunoprecipitation assays
ChIP assays were performed according to the X-ChIP protocol (Abcam).
In brief, cells were fixed for 10 min in 1% formaldehyde, placed in lysis buffer
(50mM TrisHCl (pH 8.0), 10mM EDTA, 1% SDS), and then chromatin was
sheared into 500 bp to 1000 bp fragments by sonication. Equal amounts of
sample were immunoprecipitated with 2.5µg of anti-SRF (Santa Cruz), or anti-
flag (Sigma) Ab. ChIP PCRs were performed using Red Taq ReadyMix (Sigma)
using primers that were previously described (104).
Results
Identification of T159 as a potential phosphorylation site that inhibits SRF
activity
Because little is known about the effects of SRF phosphorylation on SMC-
specific transcription we decided to take a broad approach to identifying
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potentially important phosphorylation sites. Based upon previous reports on SRF
phosphorylation, we screened a series of phosphorylation mutants (T/S to A) and
phospho-mimetics (T/S to D/E) (see figure 2.1a) for their ability to alter SMC-
specific promoter activity in SRF -/- ES cells. The SRF -/- ES cells used are
stable when grown in LIF containing media and have similar proliferation rates to
Wt ES cells (6). However, SRF -/- ES cells have an impaired immediate early
growth response and do not express SRF-dependent muscle specific markers
such as cardiac-, skeletal-, and SM α-actin (175, 208).
As expected, the SM22 and SM α-actin promoters were virtually inactive
in SRF-/- ES cells but were strongly stimulated (by 12 and 50 fold, respectively)
by co-transfection of Wt SRF (figure 2.1b). Few of the SRF phosphorylation
variants tested had significant affects on SMC-specific promoter activity in this
model. However, the phosphomimetic mutation T159D almost completely
inhibited SRF's effects on the SM α-actin promoter (fig 2.1c) and reduced SM22
promoter by about 60%. In excellent agreement with a previous study by Iyer
et.al. (79), the S162E phosphomimetic also dramatically inhibited the activity of
both promoters providing significant validation of our screening approach. The c-
fos promoter exhibited relatively high basal activity in the SRF -/- ES cells and
was only stimulated 4 fold by expression of Wt SRF suggesting that its activity
was less dependent upon SRF. Nevertheless, SRF-dependent activation of the
c-fos promoter was attenuated by the T159D and S162E mutations. Importantly,
there were no differences in protein expression of the SRF variants (fig 2.1d).
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T159 was phosphorylated by protein kinase A
Sequence analysis revealed that T159 conforms to a consensus
phosphorylation site for cAMP and cGMP-dependent protein kinases, RRXS/T
(fig 2.2a). As a first step to determine whether PKA or PKG could phosphorylate
T159, we performed in vitro kinases assays. A GST fusion protein containing the
N-terminal third of SRF (AA1-203) was incubated with purified active PKG or
PKA. As shown in figure 2.2b, both of these kinases strongly phosphorylated the
Wt construct and this phosphorylation was dramatically inhibited by the T159A
mutation. To test whether these kinases could phosphorylate SRF in vivo, we
transfected full length flag-tagged SRF into Cos-7 cells and activated PKA or
PKG by treatment with forskolin or 8-pCPT-cGMP, respectively. Since Cos-7
cells express very low levels of PKG, the cells to be treated with 8-pCPT-cGMP
were co-transfected with PKG.  As shown in figure 2.2c, treatment of cells with
forskolin resulted in a significant increase in 32P incorporation in SRF
immunoprecipitants and this increase was completely abrogated by the T159A
mutation. Activation of PKG failed to significantly increase SRF phosphorylation
even though these conditions lead to substantial phosphorylation of the PKG
substrate VASP (data not shown).  To test whether SRF was phosphorylated by
PKA in SMC, we treated 32P labeled primary rat SMC cultures with forskolin and
immunoprecipitated endogenous SRF. Although SRF was phosphorylated to
some extent under basal conditions, activation of PKA increased this signal (fig
2.2d). Taken together these results indicate that T159 is a target for PKA in SMC.
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Figure Legend 2.2  PKA phosphorylated SRF T159 in vitro and in vivo.
A) SRF sequence conservation near the consensus PKA/PKG phosphorylation
site at T159  B) GST-SRF fusions (AA 1-203) containing Wt or T159A protein
sequence were incubated with γ32P-ATP in the presence of active PKA or PKG
for 15 min. Following removal of unincorporated label, samples were separated
on an SDS-Page gel and exposed to film. C) Cos-7 cells expressing flag-tagged
Wt and T159A SRF were incubated with 1mCi ortho 32P for 2h and then
stimulated with 20µM forskolin or 100µM 8-pCPT-cGMP for 2.5h. SRF was then
immunoprecipitated from RIPA lysates using anti-flag agarose. Following
washing immunoprecipitants were run on an SDS-Page gel, transferred to
nitrocellulose, and exposed to film. D) Primary SMCs were treated with FSK or
100µM 8-pCPT-cGMP for 2.5h and endogenous SRF was immunoprecipitated
with an anti-SRF Ab.
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SRF T159D had promoter-specific effects on myocardin factor
transactivation
Since SMC differentiation marker gene expression is regulated mainly by
SRF’s interaction with the myocardin family of cofactors, we next tested the
functional significance of the SRF T159 phosphomimetic on SM α-actin and
SM22 transactivation by these factors. As shown in figure 2.3a, expression of
myocardin factors in SRF -/- ES cells strongly increased SM α-actin promoter
activity only in the presence of Wt SRF and the T159D mutation almost
completely inhibited this response.  Interestingly, as shown in 2.3b, the T159D
mutation had no effect on SM22 promoter activity when co-expressed with the
myocardin factors suggesting that the effects of this mutation could be rescued
under some circumstances. The S162E mutation strongly inhibited both
promoters under these conditions.
Phosphorylation of T159 inhibited SRF-CArG binding
T159 is located within the amphipathic αI helix of the SRF MADS box that
interacts with the CArG element. It lies on the same helical face as S162, and
like S162, has been shown to interact with nucleotides flanking the CArG
sequence (136, 155). Given that S162 phosphorylation inhibited SRF-CArG
binding (79), we hypothesized that the inhibitory effects of the T159D mutation on
SMC-specific transcription were due to a similar mechanism. To test this, we
measured the binding of Wt SRF and SRF phosphorylation variants to CArG
elements using gel shift assays. As shown in figure 2.4a, incubation of in vitro
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translated Wt flag-tagged SRF with the SM α-actin intronic CArG resulted in a
prominent complex that was supershifted by the addition of anti-flag Ab. SRF
binding was slightly reduced by the T159A mutation but was completely inhibited
by both the T159D and S162E mutations (lanes 4 And 5). As shown in lanes 6-
13 the addition of myocardin or ΔNMRTF-A resulted in the formation of a ternary
complex with Wt SRF, but not with the T159D or S162E SRF variants.
Interestingly, the results of gel shift assays with the SM22 far CArG were
slightly different (fig 2.4b). First, the T159A mutation had much less of an effect
on SRF binding and myocardin factor complex formation. More importantly, the
presence of myocardin (and to a lesser extent ΔN-MRTF-A) could partially
restore binding of the T159D variant to the SM22 far CArG (see fig 2.4b; lane 8).
These data support previous studies from our lab indicating that differences in
CArG and/or CArG flanking sequence have important effects on
CArG/SRF/myocardin factor ternary complex formation (69) and indicate that
SRF phosphorylation may have preferential effects on certain CArG-dependent
genes. In addition, these data likely explain the ability of the myocardin factors to
rescue the effects of the T159D mutation on SM22 promoter activity.
To test whether T159 phosphorylation affected SRF binding in vivo, we
first performed chromatin immunoprecipitation (ChIP) assays in SRF -/- ES cells
expressing Wt and T159D SRF. If SRF was present at the CArG-containing
regions of the SMC-specific promoters upon fixation, then these promoter
fragments would be detected by PCR in SRF immunoprecipitates.  As shown in
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Figure Legend 2.4  Phosphorylation of T159 inhibited SRF binding to the
SMC-specific CArGs.  Radiolabeled 50bp oligonucleotide probes containing
either the SM α-actin intronic CArG (A) or the SM22 far CArG (B) were incubated
with the indicated SRF variant in the absence or presence of myocardin or
ΔNMRTF-A.  All proteins were in vitro translated and the total amount of TnT
protein in each reaction was maintained by the addition of unprogrammed lysate.
After 30 min binding reactions were run on a 5% non-denaturing gel, transferred
to filter paper, and visualized by autoradiography. For supershifts (lane 1), 1µL of
anti-flag antibody was added after 20 minutes of incubation. C) SRF -/- ES cells
were transfected with Wt or T159D SRF. After 48h cells were processed for ChIP
assays by standard protocols (see methods for more details). PCR reactions
were performed on immunoprecipitants using primers spanning the SM α-actin
intronic CArG, the SM22 far CArG, and the c-fos SRE. D) SMCs grown in 10%
FBS were treated with 20µM forskolin or vehicle for 2.5h before processing for
ChIP assays.
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figure 2.4c, the binding of the T159D SRF variant to the SM22 and SM α-actin
promoters was considerabley weaker than that observed with Wt SRF.  We also
used ChIP assays in primary SMC to demonstrate that the interaction of
endogenous SRF with the SMC-specific promoters was inhibited by forskolin
treatment (figure 2.4c, right panel). Interestingly, SRF binding to the CArG-
containing region of the c-fos promoter was unaffected by the T159D mutation or
forskolin treatment.
The T159D mutation inhibited SMC differentiation of ES Cells
The results presented so far indicate that SRF is phosphorylated by PKA
at T159 and that this phosphorylation can inhibit SMC-specific promoter activity.
To further test this regulatory mechanism on SMC differentiation, we used a
previously described monolayer ES cell model in which endogenous SMC
differentiation marker gene expression is induced by removal of LIF and addition
of retinoic acid (161, 175, 208). As expected, SMC differentiation marker gene
mRNAs were not detected in SRF -/- ES cells transfected with empty expression
vector at any time-point of the differentiation protocol. In contrast, transfection of
Wt SRF into SRF -/- ES cells induced endogenous SM α-actin and SM22
message levels by 55 and 20 fold, respectively, and these levels were further
increased at day 3 and day 6 of the differentiation protocol (figure 2.5a). The
T159D and S162E mutations significantly reduced SM α-actin and SM22
message levels at day zero and prevented any further increase in message
levels at the later time-points (figure 2.5b). Interestingly, the T159A mutation
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actually increased SM22 message levels suggesting at least some basal SRF
phosphorylation under these conditions.
Finally to determine the overall effects of PKA on SRF-dependent gene
expression in mature SMC, we treated primary rat aortic SMC with forskolin. As
shown in figure 2.6, forskolin dramatically inhibited SM α-actin and SM22
promoter activity but had only minor effects on c-fos.
Discussion
Extensive evidence indicates that SRF plays a critical role in the regulation
of SMC-specific and early response growth gene expression, and a major goal of
these studies was to identify signaling mechanisms that regulate SRF's
involvement in these disparate gene programs. Although many kinases have
been identified that phosphorylate SRF, the significance of these modifications in
regard to the regulation of SMC-specific gene expression are somewhat unclear.
Thus, in the present study we used a relatively unbiased approach to identify
phosphorylation sites on SRF that regulate its ability to drive SMC-specific
expression.  By expressing phosphorylation mutants in SRF -/- ES cells, we
identified T159 as a phosphorylation site that negatively regulates SRF activity by
inhibiting its interaction with SMC-specific CArG elements. T159 was
phosphorylated by PKA in vitro and in vivo suggesting that this signaling
mechanism may regulate SMC phenotype. Our results also confirm a previous
study by Iyer et.al. demonstrating that phosphorylation of S162 strongly inhibited
SRF-dependent SMC-specific transcription (79).
54
55
Several studies have characterized SRF's interaction with CArG-
containing oligonucleotides, and the major contacts between SRF and DNA are
between the basic residues within the SRF αI helix and the core CArG sequence
(57, 136, 155). However, as shown in the original crystal structure of the core
SRF dimer bound to DNA (155), T159 and S162 of one SRF αI helix contact a
residue on the 5' flank of the CArG element (155). Interestingly, Mo et al.
demonstrated that the presence of the SRF accessory protein, SAP-1, within the
ternary complex significantly increased SRF contacts with the CArG flanking
regions of the c-fos SRE including additional interactions between S162/T159 on
the second αI helix with a thymine residue to the 3' side of the CArG box (136).
Thus, the inhibitory effects of the T159 and S162 phosphorylation observed in
the present studies are consistent with the importance of these residues for
SRFs interaction with DNA. Interestingly, a similar crystal structure study on the
SAP-1-containing ternary complex by Hassler et. al. did not detect an interaction
between T159 and CArG flanking sequence (57).  Although the precise nature of
this discrepancy is somewhat unclear, the CArG-containing oligonucleotide used
by this group was substantially different suggesting that sequence variations
within or flanking the CArG element may play a role in determining SRF
conformation in the ternary complex. Our demonstration that the myocardin
factors could specifically rescue the effects of the T159D mutation on SRF
binding to and activation of the SM22 promoter indicates that the myocardin
factors alter SRF-CArG interactions and supports the idea that sequence
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variation within the CArG or CArG flanking regions plays an important role in this
mechanism.
Our results could have important implications on control of SMC
phenotype by environmental cues that regulate cAMP levels. A previous study by
Davis et. al. demonstrated that activation of PKA in rat aortic SMC inhibited while
dominant negative PKA enhanced SRF-dependent transcription (29).
Subsequently, this group showed that activation of PKA by the Gαs-coupled
agonists, isoproterenol and ATP, resulted in a decrease in endogenous SMC
differentiation marker gene expression (72). In contrast, Fetalvero et al.
demonstrated in human aortic SMC that the prostacyclin analog, iloprost,
enhanced SMC differentiation marker gene expression by a mechanism that was
dependent upon PKA (40). Although the discrepancy between these studies
could be explained by species differences, it is also possible that agonist-specific
differences in the level, timing, or localization of PKA activation by these agonists
may also play a role. Of interest, genetic deletion of the inhibitory RIα subunit of
PKA in the mouse (which led to constitutive PKA activity) resulted in defective
mesoderm formation (4), a phenotype very similar to that observed in SRF knock
out mice (6, 208).
Activation of PKA has many affects in the cell and its ability to inhibit SRF
binding to SMC-specific CArG elements may only partially explain its effects on
SMC-specific transcription. Indeed, it is well known that PKA antagonizes RhoA-
dependent signaling in a variety of cell types (including SMC) resulting in
inhibition of actin stress fiber formation (71, 143).  Since we have shown that
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actin polymerization positively regulates SMC-specific transcription by enhancing
the nuclear localization of the MRTFs (69, 103, 189), PKA likely inhibits SMC-
specific transcription by multiple mechanisms. Interestingly, PKA and RhoA
signaling also have antagonistic effects on SMC contractility, and we postulate
that these pathways may act in combination to couple agonist-induced changes
in SMC contractility to subsequent changes in contractile protein gene
expression.
Several lines of evidence from the current study indicated that T159
phosphorylation has less of an effect on c-fos promoter activity. First, the overall
activity of the c-fos promoter was less dependent upon the presence of SRF.
Second, SRF binding to the c-fos SRE in ChIP assays was not affected by the
T159D mutation or forskolin treatment. These results likely reflect the
stabilization of SRF binding to the c-fos SRE by the TCFs (79).  Finally, PKA
treatment of SMC resulted in a relatively small reduction in c-fos promoter
activity. Because the c-fos promoter is also regulated by a cAMP response
element, the positive effects of PKA on CREB may limit the negative effects of
PKA on SRF. While most previous studies suggest that PKA activation inhibits
SMC proliferation (see (10) for review), our data suggest that it may be more
important for down regulating the SMC differentiation gene program.  Clearly,
SMC growth and differentiation are not mutually exclusive (152) and PKA
signaling may have independent effects on these important SMC parameters.
Our results are somewhat contrary to an earlier study demonstrating that
T159 phosphorylation enhanced SRF's ability to stimulate cardiac α-actin
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promoter activity in CV-1 cells (78). In the original report of these results, the
T159D mutation did not affect SRF binding, and the positive effects of the T159D
variant were attributed to increased association of SRF with additional
transcription factors such as GATA-4 and Nkx2.5.  However, these authors
recently published an erratum to this manuscript that was prompted by the
discovery of a sequencing error in their T159D construct (Biochemistry. 2008 Feb
5;47(5):1464). Although they now conclude that the T159D mutation inhibits SRF
binding, they confirmed that this mutation increases cardiac α-actin-promoter
activity in CV-1 cells. ES cells grown in monolayer culture do not express Nkx2.5
and Gata-4 (15, 23) and the lack of this (or some other) positive transcription
factor interaction could help explain this discrepancy. It is also important to note
that these authors demonstrated that T159 was a possible substrate for DMPK
and PKCα. In the current study, we focused on the role of PKA because it had
previously been shown to have negative effects on SMC-specific transcription.
While, we cannot rule out that DMPK and/or PKCα phosphorylate SRF at T159,
our data indicate that such a modification would inhibit SMC-specific
transcription.
In summary, the results from the present study indicate that
phosphorylation of SRF at T159 by PKA inhibits SMC-specific transcription by
inhibiting SRF's interaction with CArG elements. The promoter specific effects of
this modification in the presence of the myocardin factors suggest that it may be
an important mechanism by which SRF differentially regulates the many genes
that are CArG-dependent. Thus, it will be critical to further investigate the role of
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PKA signaling on SMC phenotype and to identify the consequences of this
modification on SMC function.
Acknowledgements
This work was supported by NIH Grants HL-070953 (CPM) and HL-
071054 (JMT).
CHAPTER III
Potential Regulation of SRF-Depenedent Gene Expression
by SRF Sumoylation
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Introduction
Extensive evidence indicates that the MADS (MCM1, Agamous, Deficiens,
SRF) Box transcription factor SRF is a critical regulator of VSMC differentiation.
SRF specifically binds cis promoter CArG (CC(A/T6)GG) elements, which are
present in nearly all VSMC promoters and whose deletion results in elimination of
expression of the gene (1, 64, 109, 113, 118, 130, 137, 226).  Correspondingly,
the SRF null mouse dies due to mesodermal differentiation defects (6).  As SRF
expression is ubiquitous, there are many additional mechanisms that are
required for myogenic development.
The myocardin family of transcription factors have also been identified as
strong transactivators of VSMC-specific expression and are required for
differentiation of some SMC subsets.  Myocardin and the two Myocardin-Related-
Transcription Factors (MRTF-A and -B) do not have a consensus DNA binding
region, although they powerfully transactivate myogenic-specific gene expression
through their interactions with SRF (21, 34, 206, 229).  Additionally, RhoA
signaling can increase MRTF-A and -B-induced gene activity by increasing their
nuclear translocation (69).
SRF is also regulated by many post-translational events, including
phosphorylation of at least 10 documented sites (45, 78, 80, 119, 123),
glycosylation (166), and most recently sumoylation (125).  We first became
interested in sumoylation as a mode of regulating SRF upon identification of the
small ubiquitin-like modifier (SUMO) conjugating enzyme, Ubc9, as an SRF
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binding partner in a yeast-2-hybrid screen that was performed in rat aortic
VSMCs.
The first member of the SUMO family, SMT3, was reported in yeast in
1995 by Meluh and Koshland (128).  It was identified in a screen for suppressors
of a temperature sensitive MIF2.  Subsequently, several mammalian homologs
were identified using a number of screens, which identified its potential use in a
variety of pathways (9, 121, 149).
Sumoylation is the covalent addition of the 101 amino acid SUMO protein
to a targeted lysine residue that is surrounded by the consensus motif ψKxE,
where ψ is a hydrophobic residue and x is any amino acid.  Sumoylation occurs
by a three-step mechanism that involves an activating enzyme (Aos1/Uba2 in
yeast), a conjugating enzyme (Ubc9), and finally a specific ligase (such as Pias1)
(127).
The consequences of protein sumoylation vary, but may involve regulation
of sub-nuclear protein localization, chromatin remodeling, or protein stability
(127).  The list of proteins that are “sumoylated” is growing rapidly and includes
the tumor suppressor, p53, the nuclear import regulator, RanGAP1, and the
transcription factor, c-jun (174, 233).
Recent studies have revealed a link between sumoylation and protein
stability.  For instance, sumoylation of IKKγ (an enzyme regulated by ubiquitin
degredation) enhances IKKγ stability by targeting the protein to deubiquitinating
enzymes (75).
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Sumoylation has been identified as a regulatory event of a growing list of
transcription factors.  In a few reported cases, transcription factor sumoylation
increases transcription, although this modification more frequently represses
transcription.  Heat shock transcription factors (HSF1 and HSF2), nuclear factor
of activated T cells (NFAT-1), and p53 tumor suppressor are transcription factors
in which sumoylation correlates with an increase in transcriptional levels.   In
cases where sumoylation represses transcription, the modification frequently
occurs at known repressor regions in the transcription factor, such as in Elk1.
SUMO-Elk-1 recruits histone deacetylase 6, which promotes a repressed
chromatin conformation.  Phosphorylation of SUMO-Elk-1 via the ERK MAP
kinase pathway stimulates removal of SUMO and therefore a transcriptionally
active promoter.  SUMO’s affect on transcription is context specific.  For
example, Smad4 transcription factor sumoylation increases transcription of some
promoters and represses transcription of others.  This sumoylated Smad4 has
subsequent interactions with E3 ligases that affect promoter activity (61). Clearly,
there are many levels in which sumoylation could change transcriptional activity
of the modified transcription factor.
In 2005 MKL1, the human isoform of Myocardin-related transcription factor
A, was identified as a substrate for sumoylation and that this sumoylation occurs
in the presence of serum stimulation or constitutively active RhoA.  However, this
modification results in a decrease in the transcription capability of MKL1 on
serum response element-driven luciferase (139). The serum response element is
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usually associated with growth genes, it contains the CArG, but is not SMC or
myogenic specific.
In January 2007, Wang et. al. determined that sumoylation of myocardin
activates cardiac-specific gene expression (22).  As myocardin is expressed
specifically in cardiac and SMCs, this could be a mechanism that distinguishes
the specification of these two myogenic lineages.
There is recent evidence of sumoylation in many proteins that are involved
in SMC-specific gene expression.  Myocardin is sumoylated (202) as well as the
growth gene cofactor elk1 (which has a repressive phenotype) (222).
Additionally, TGFβ, a strong regulator of myogenesis, has enhanced activity
when the receptor is sumoylated (135).  SRF was also implicated as a target of
SUMO modification in 2003 by Matsuzaki et. al (125).  As an additional potential
source of SRF regulation, we sought to test the hypothesis that sumoylation
regulates SRF-dependent SM-specific transcription.
Methods
Confirmation of SRF and Ubc9 interaction
Full length SRF Wild typewas cloned into the pGEX-4T1 expression
plasmid (Amersham).  GST-fusion SRF protein was expressed in and affinity
purified from BL21 bacteria by standard methods. Purified GST-fusion protein
bound to glutathione sepharose was washed 3 times and resuspended in TBS.
Promega Tnt in vitro translation kits were used to prepare 35S-Ubc9.  GST-SRF
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was used incubated with the radiolabeled Ubc9, and the interaction was detected
by radiography.
In vitro sumoylation assays
SRF K147R was cloned into the pGEX-4T1, full length SRF Wild type and
K147R GST-fusion proteins were prepared as described above, and
ressuspended in TBS.  Sumoylation reactions (Active Motif SUMOlink SUMO-1
kit) were performed at 30oC for 3h and contained 0.5µg GST-fusion protein or
p53 positive control, supplied buffer, and either wild-type SUMO-1 or the mutated
SUMO-1 in a 20µL reaction. Sumoylation of substrate was observed by
immunoblot using SRF (Santa Cruz), p53, and SUMO-1 antibodies (Active Motif).
In vivo sumoylation assay
Primary cultured rat aortic VSMCs were serum starved for 17h, followed
by TGFβ  treatment for 7h.  Cells were harvested and SRF was
immunoprecipitated using the polyclonal SRF antibody (Santa Cruz G20).  The
immunoprecipitation was analyzed by SRF and SUMO-1 immunoblot.
Cell culture and promoter assays
SRF-/- embryonic stem cells were a generous gift from Alfred Nordheim
(6, 208) and were cultured per referenced protocol except cultures were
maintained in 5% CO2.  Briefly, cells were maintained on 0.1% gelatin coated
plates in DMEM plus 15% ES Qualified FBS, 50U/mL penicillin, 50µg/mL
streptomycin, .1mM β-mercaptoethanol, and 1000U/mL Leukemia inhibitory
Factor (LIF).  Conservative point mutations in the pcDNA3.1-Flag-SRF were
achieved by sequence overlap extension to change potential sumoylation target
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lysine residues to a substrate that cannot be sumoylated (arginine).  SRF
constructs and promoter-luciferase constructs were transfected using Mirus LT1
transfection reagent per protocol.  Luciferase activity was measured 24h post-
transfection and is expressed relative to plus empty vector (n equal to 3 or more
independent transfections).  For protein expression cells were harvested in RIPA
buffer plus inhibitors as previously described (189).
Electromobility shift assays
For the electromobility shift assays, protein was prepared using the T7
TnT-Quick in vitro transcription/translation kit (Promega) from pcDNA3.1-Flag-
SRF (Wild typeor mutants) and Flag-pcDNA3.1-Myocardin 807 (lacking the first
128 amino acids) or Myocardin Related Transcription Factor-A and B (MRTF-A
and MRTF-B) ΔN (lacking the first 80 amino acids).  Oligonucleotides were
purchased from the UNC Pathology Oligonucleotide Laboratory and include the
SM α-actin Intronic CArG probe.  Binding reactions contained 2µL SRF and
cofactor, 40,000 counts/min of 32P end-labeled probe, 0.20µg dIdC, and 1X
binding buffer (10mM Tris, pH 7.5, 50mM NaCl, 100mM KCl, 1mM DTT, 1mM
EDTA, and 5% glycerol).  Sigma Flag M2 antibody was used for supershifts (data
not shown) and were added to reactions 20 mins into the 30 min incubation.
Differentiation protocol and Quantitative RT-PCR
SRF -/- ES cells were cultured as described above until 24h post-
transfection.  At 24h post-transfection (considered differentiation day 0) plates
were washed 2 times in 1X PBS and the differentiation media was applied.
Differentiation media is the ES culturing media described above except that it
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lacks LIF and retinoic acid (5 X 10-7M) is added to stimulate differentiation, as in
the protocol by Philippar et al (161).  RNA was collected in TRIzol (Invitrogen) at
differentiation day 0, day 3, and day 6 and analyzed by quantitative RT-PCR.
Reactions contained SM α-actin primers and probe multiplexed with the
endogenous control gene 18S in a 30µL PCR reaction. Primers used in these
reactions were: SM α-actin forward (CGC TGT CAG GAA CCC TGA GA), SM α-
actin reverse (CGA AGC CGG CCT TAC AGA G), and SM α-actin probe (FAM-
CA GCA CAG CCC TGG TGT GCG AC –Tamra).  18S primers and probe were
a generous gift provided by Hyung-Suk Kim.  The SM α-actin reactions contained
20µM probe, 0.05µg forward and reverse primers, and 200ng RNA. For relative
quantification the threshold cycle (Ct) of an endogenous control gene (18S) was
subtracted from the gene of interest in the corresponding sample well.  This gives
the difference in Ct and the relative quantification value is then expressed as 2-
ΔCt.  Then the relative quantification value is shown as relative to plus empty
vector at zero days of differentiation to make the comparison of the SUMO-
defective SRF- induced expression to that of Wild type SRF.
SRF mutant localization
SRF -/- ES cells transfected with SUMO-defective SRF variants were
analyzed by immunohistochemistry, using the Flag M2 monoclonal antibody
(Sigma) and DAPI staining.
68
Results
The E2 enzyme, Ubc9, interacted with SRF
We first became interested in the possibility of SRF as a target of covalent
SUMO modification when the E2 sumoylation enzyme, Ubc9, was identified as
an SRF binding partner.  A screen performed against a rat aortic SMC library
using full-length SRF as bait (performed by CP Mack) and the interaction was
confirmed using GST-SRF to pull down in vitro translated 35S-Ubc9 (interaction
confirmed by AL Blaker)(Figure 3.1B).
Ubc9 catalyzes the addition of SUMO to substrates containing the
consensus motif, of which SRF has at four sites, SRF lysines 99, 147, 324, and
506 (Figure 3.1A).  Thus, we sought to determine whether this event occurs in
SMCs and whether SRF sumoylation is a regulator of SM-specific transcription.
SRF is sumoylated at K147
To test whether SRF was sumoylated, in vitro sumoylation reactions were
performed (Figure 3.2A).  In brief, Gst-SRF protein was purified from bacterial
expression and used as a sumoylation substrate. A mutated version of the
SUMO 1 protein that cannot be conjugated to substrate was included as a
negative control and p53 was included as a positive control substrate.  A
consensus sumoylation sequence IKME was identified in the SRF protein
sequence at (AAs 146-149), and several other weak consensus sites were also
identified.  The covalent addition of the 101 amino acid SUMO protein occurs at
the lysine residue in this sequence.  By mutating SRF K147 to an arginine, we
significantly inhibited sumoylation of SRF protein (Figure 3.2B).  This result
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suggests that SRF K147 is the primary site of sumoylation, although it does not
exclude the other sites as target residues.
Next we attempted to show whether SRF sumoylation occurs in VSMCs.
As we were unable to show sumoylation in a simple SRF immunoprecipitation
followed by an immunoblot for SUMO-1, we hypothesized that SRF sumoylation
may occur during specific genetic program event and therefore treated the SMCs
with TGFβ  to stimulate the SMC-specific program.  After SRF
immunoprecipitation, the SRF immunoblot confirmed the presence of SRF at 67
kDa, as well as a band at 170 kDa.  Interestingly, 170 kDa is the same size of the
sumoylated SRF that was identified in vitro (Figure 3.2C).  However, the SUMO-1
immunoblot did not yield a band at the appropriate size and therefore we cannot
confirm that SRF is sumoylated in primary cultured VSMCs.
Mutation of K147 SRF has no affect on SM-specific promoter activity.
Next we asked whether eliminating sumoylation would affect SM-specific
transcription. Compared to Wild typeSRF, SUMO-defective SRF variants (K99R,
K147R, K324R, and K506R) transfected into the SRF -/- ES cells did not identify
a significant difference in SM22, SM α-actin, or cfos promoter activity (Figure
3.3A).  SM α-actin promoter activity also was not affected by the SRF K147R
mutation when the transfections were instead performed in NIH 3T3 cells (Figure
3.3B).  We next hypothesized that when the system is stimulated we may be able
to identify a difference in the transactivation capabilities of SRF.  Therefore,
SRF-/-  ES cells were transfected with Wild typeSRF and SRF K147R variants
and treated with either  vehicle or TGFβ for 7 hours.  We observed no difference
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between Wild typeand K147R SRF-induced SM22 promoter activity and
importantly, also did not see an increase in TGFβ-treated SRF variants
compared to vehicle treated (n=3) (Figure 3.3C).  It is possible that the SRF -/-
ES cells are lacking some of the machinery that is present in SMCs and 10T1/2
cells where the TGFβ response is typically observed.  Next, SRF -/- ES cells
cotransfected with SRF variants, myocardin family cofactors, and the SM22-
luciferase construct also did not yield any differences between Wild type and
K147R SRF variants (Figure 3.3D).  This suggests that there is no difference
between Wild type SRF and SRF K147R promoter and cofactor binding
interactions.
SRF/CARG binding affinity
SRF binds DNA directly and its affinity for promoter CArG elements can
be regulated by post-translational modifications.  To determine whether K147 can
modulate SRF affinity we employed an in vitro electro-mobility shift binding
reaction with epitope tagged SRF variants produced by in vitro
transcription/translation (Figure 3.4A).  The SM α-actin intronic CArG is the
strongest of the three SM α-actin CArGs and was selected for initial experiments.
We found that all SUMO-defective SRF variants bound the SM α-actin intronic
CArG with the same tenacity.  As we had hypothesized that SRF K147R would
be the most affected in its CArG and cofactor interactions, we included this
variant in a reaction with Myocardin 807.  The higher order complex that forms
between SRF and cofactor on the SM α-actin intronic CArG was equally strong in
the presence of the K147R mutation.  Next we addressed whether a difference in
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affinity exists among the myocardin family members, MRTF-A and MRTF-B
(Figure 3.4B).  Although MRTF-A and MRTF-B have slightly weaker interactions
with SRF, there is still no difference between Wild type SRF and SRF K147R.
We also performed this experiment using the SM α-actin CArG B because this
element has an intermediate affinity for SRF, which should allow more sensitive
detection of positive and negative changes in SRF complex formation (data not
shown).  Additonally, these experiments were performed using graduated
amounts of in vitro translated SRF protein, and yet not difference was observed
between the Wild typeSRF and SRF K147R variants (data not shown).  The
presence of a higher order complex between myocardin and SRF was confirmed
by subsequent studies in which specific epitope tag antibodies were added
during complex formation to "super-shift" the protein/DNA complex.
SRF K147R had no effect on endogenous SM α-actin in differentiation stimulated
SRF -/- ES Cells
We sought to determine whether the SUMO-defective K147R SRF would
perform a regulatory function in endogenous gene regulation.  SRF -/- ES cells
were used in differentiation assays where differentiation is stimulated by removal
of leukemia inhibitory factor and addition of retinoic acid (Figure 3.5).  Effective
stimulation of the SRF -/- ES cell differentiation system was shown by the
increase in transcript levels of endogenous SM α-actin after 3 and 6 days of
differentiation.  At 0, 3, and 6 days of differentiation the SM α-actin transcript
level induced by SRF K147R was no different than the transcript level induced by
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Wild type SRF.  These results suggest that the SRF K147R SUMO-defective
variant also has no affect on the regulation of endogenous VSMC phenotype.
SRF Variants Localize to the Nucleus
SUMO-defective SRF variants expressed in SRF -/- ES cells were
immunostained using the flag epitope tag and DAPI in order to confirm nuclear
localization.  All variants were localized to the nucleus as expected (Figure 3.6).
As it was previously suggested that SRF may interact with promyelocytic
leukaemia (PML) nuclear bodies (125), we also immunostained for PML (data not
shown).  Although there is no apparent difference in nuclear localization, it is
possible that SUMO-SRF localizes to distinct sub-nuclear compartments.  One of
particular interest is PML bodies, which are made of a particular set of proteins
that exist in a dynamic equilibrium with their surroundings.  Sumoylation
participates in the subnuclear assembly of PML nuclear bodies and chromatin
loops.  Although the exact function of PML bodies is yet unclear, its association
and dynamic exchange with nuclear components suggest that it may have a role
managing subnuclear activities (65).
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Discussion
In agreement with Matsuzaki et al 2003 (125), experiments presented
here suggest that lysine 147 is the primary site of SRF sumoylation.
Following the initial observation and confirmation of SRF’s interaction with
the E2 conjugating sumoylation enzyme Ubc9, we also confirmed that SRF is
primarily sumoylated at K147 in vitro.  Although sumoylation of SRF at K147 was
identified by Matsuzaki et. al. in HeLa cells (125), we attempted to confirm the
covalent modification occurs in VSMCs.  The attempt was not successful and
additional experiments using SUMO-defective SRF variants showed no
difference when compared to Wild type SRF.  Data presented here suggest that
SUMO-defective SRF is fully functional in SMC-specific gene expression.
Sumoylation has a regulatory effect in development
Myoblast regulation by SUMO is required in skeletal muscle development.
During skeletal muscle development myoblasts fuse to form myotubes.
Riquelme et. al. have shown that  in C2C12 cells, the SUMO conjugating
enzyme, Ubc9, is required for myotube formation(167).  In a C2C12 myoblast
differentiation protocol, cells exposed to Ubc9 siRNA have a decrease in
myotube formtion.  The authors did not find a difference in the expression or
activity of MyoD or myogenin.  However, they did find that the overall number of
sumoylated proteins in myoblasts decreases as the cells progress through
myogenesis.  These findings support the hypothesis that sumoylation plays an
important role during myogenic development (167).
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The covalent SUMO modification is a reversible process, which allows an
additional level of substrate protein regulation.  This regulation can occur at
specific stages and tissues in the embryonic development (231).  In mammals,
sentrin-specific proteases (SENP) are responsible for the deconjugation of
SUMO from the targeted protein (138). Desumoylation by at least one homolog,
SENP1, is essential for mouse development.  Mutation of SENP1 by random
retroviral insertion in vivo results in increased sumoylated forms of proteins and
in defects in the placenta.  These effects render the SENP1-deficient animals
discordant for embryonic development. Maternal and fetal blood spaces are
decreased, and by E12.5 the embryos begin to suffer from a low gas and nutrient
exchange. These animals also have pooling of blood in the trunk region between
E13.5 and E14.5 (219).  Although SENP1 regulates the steady-state of
sumoylated forms of a variety of proteins, there is a clear defect in the formation
of vascularization required to sustain life, supporting the role of sumoylation in
development.
Matsuzaki et. al. showed potential sumoylation of SRF in HeLa cell
extracts although the transient nature of the modification has made it difficult to
show.  Growth gene promoter assays suggested a Rho A-induced increase in c-
fos promoter activity that is greater in the SUMO-defective mutant than in the
Wild type SRF (125).  Activated RhoA is a potent stimulator of SM-specific genes
(3, 103), which is not addressed in the previously mentioned work.  The c-fos
promoter is one of many growth genes that are also stimulated by SRF.
However, SRF activation of the growth genes is associated with the proliferative,
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synthetic program, which somewhat excludes activation of the SMC-specific
genes.  Therefore, experiments were performed to delineate whether
sumoylation of SRF is a regulatory mechanism of SM-specific expression.
SMC-specific genes and growth genes that are regulated by SRF differ in
conserved promoter sequences, interactions with cofactors, and in post-
translational modifications that dictate some of these interactions. The c-fos
promoter has an ETS domain in addition to the CArG box.  An additional
transcription factor, such as the ternary complex factor Elk-1, binds the ETS
domain and interacts with SRF, which binds the CArG box and promotes
transcription.  Sumoylation of Elk1 regulates its activity on multiple levels.  First,
Elk1 contains two autoregulatory domains that function by repressing its two
activation domains.  Sumoylation of the included R motif is required in order for
repression to occur(221).  Secondly, Elk1 sumoylation enhances nuclear
retention(172).  Finally, SUMO modified Elk1 interacts with Piasx.  Although the
Pias family of proteins is often associated with the sumoylation pathway as the
E3 ligase, its interaction with Elk1 is independent of this function.  The Piasx
interaction with Elk1 requires that Elk1 already be sumoylated and the interaction
derepresses the Elk1 transcriptional activity through decreasing its interaction
with histone deacetylases (HDAC) (225).  There is evidence that sumoylation of
histones promotes association with HDACs (47, 179, 223), leaving the model as
SUMO-Elk1 represses transcriptional activities, but Piasx association can
overcome this negative regulation to some degree.
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Further Experiments
As we do not know the conditions in which SRF might be sumoylated in a
cell, we also cannot dismiss the idea that it might occur with complete
confidence. SMC agonists of the contractile phenotype or of the synthetic
phenotype (ex. PDGFβ) could be used in an effort to identify whether SRF
sumoylation is employed under either genetic program.  We received a
desumoylating enzyme, SENP1, as a gift from Dr. Edward Yeh (Univ. Texas,
Houston Health Science Center) (49).  This enzyme could be transfected in
experiments testing for endogenous SRF sumoylation.  If SRF is sumoylated,
then expression of SENP1 may eliminate higher species of SRF that are
identified in immunoblots (potentially SUMO-SRF).
The close proximity of the post-translational modifications I have identified
indicates the possibility that modification of one site might alter modification of
the other.  Due to the bulky nature of the SUMO group, prior sumoylation of SRF
on K147 may attenuate subsequent PKA-induced phosphorylation on T159.
Conversely, prior phosphorylation of T159 may enhance the ability of SRF to be
sumoylated on K147.  If these sites are co-regulated in vitro, subsequent
experiments could determine whether PKA agonists enhance SRF sumoylation
in vivo, and whether these modifications are necessary for PKA-dependent
regulation of SRF gene targets using our standard promoter-reporter
transcription assays.
Additionally, sumoylation can regulate protein stability (for example see
(100)).  Although SRF does not have a short half-life, we could confirm that it is
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not being subjected to uqiquitin-mediated degradation by inhibiting the ubiquitin
proteosome (MG115 or calpain).  Protein levels would then be compared by
immunoblot.
Sumoylation is a known regulator of many transcription factors (see (107)
for review), including its activation of cardiogenic-dependent transcription by
myocardin(202).  However, we have not found evidence to support regulation of
SM-specific expression by SRF sumoylation.
CHAPTER IV
FHOD1 Regulates VSMC-Specific Gene Expression
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Introduction
Smooth muscle cells (SMC) phenotype is regulated by a complex array of
extrinsic cues, but the signaling mechanisms by which these stimuli regulate the
SMC-specific gene expression are not well understood.  Extensive evidence
indicates that the ubiquitously expressed transcription factor, serum response
factor (SRF), regulates the expression of most SMC differentiation marker genes
by binding to conserved CArG cis elements within their promoters. The
myocardin family of SRF co-factors (myocardin and the Myocardin-Related
Transcription Factors, MRTF-A and MRTF-B) are also important because these
transactivators strongly up-regulate SMC-specific gene expression and have
been implicated in the regulation of SMC differentiation in vivo. Thus, it will be
critical to identify the signaling mechanisms that regulate SRF and the myocardin
factor activity.
In an elegant series of studies, the Treisman laboratory has identified the
the small GTPase, RhoA as an important regulator of SRF/MRTF-dependent
transcription. Miralles et. al. demonstrated that MRTF-A resides nearly
exclusively in the cytoplasm under serum-starved conditions and translocates to
the nucleus upon activation of RhoA (133).  They went on to show that the
conserved RPEL domains in MRTF-A’s N-terminus interact directly with G-actin
(163) and that the reduction in G-actin pools that occurs upon RhoA-mediated
actin polymerization facilitates MRTF-A nuclear localization. We have shown that
both MRTFs are regulated by similar mechanisms in primary rat aortic SMC and
multipotential 10T1/2 cells, and that this RhoA-dependent mechanism may be
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important for regulating SMC differentiation marker gene expression in response
to extrinsic cues.  Importantly Vartiainen et al. recently demonstrated that MRTF-
A nuclear localization is regulated mainly by Crm-1 dependent nuclear export
(not cytoplasmic trapping as previously thought) and that MRTF-A binding to G-
actin in the nucleus is required for this process. Although these results suggest
that nuclear actin plays a role in regulating MRTF function, little is known about
the function of actin in the nucleus making it difficult to determine the precise
mechanisms involved.
We have previously reported that the RhoA effectors, mDia1 and mDia2,
are highly expressed in SMC and strongly upregulate SMC-specific expression
by enhancing actin polymerization (189) Thus, we are currently examining the
signaling pathways that regulate their activities. mDia1 and mDia2, along with
mDia3 and FHOD1 make up the diaphanous-related formin (DRF) sub-family that
is defined by the presence of several formin homology (FH) domains, a GTPase
binding domain (GBD), a diaphanous inhibitory domain (DID), and a diaphanous
auto-regulatory domain (DID). The general mechanisms involved in DRF
activation have been fairly well characterized (see figure 4.1C). In the inactive
state, the catalytically active FH2 domain is masked by a DRF conformation
maintained by DID-DAD binding. Crystal structure studies of mDia1 have shown
that the amphipathic DAD helix interacts with a hydrophobic pocket formed by
the DAD.  A basic region just C-terminal to the DAD helix is also important. The
binding of a small GTPase (Rho, Rac, cdc42) to the GBD (located adjacent to the
DID) sterically interferes with the DID-DAD interaction allowing the FH2 domain
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to stimulate actin polymerization in cooperation with actin-binding protein, profilin
(66, 142).
Almost nothing is known about other signaling pathways that are important
for DRF activation.  However, we have recently shown that the mDia2 DAD is
phosphorylated by Rho-kinase and that this phosphorylation inhibits the DID-
DAD interaction to enhance mDia2 activation. Importantly, Takeya et. al. have
recently shown that a similar mechanism regulates FHOD1 (194). Unlike mDia1
and mDia2, FHOD1's role in the regulation of SMC-specific transcription has not
been fully examined, making it difficult to determine whether this mechanism is
relevant to SMC phenotypic regulation.
Although the DRFs are thought to regulate cytoplasmic actin
polymerization, we have recently demonstrated that mDia2 undergoes Crm-1-
dependent nuclear/cytoplasmic shuttling. Moreover, our examination of several
mDia2 nuclear localization variants suggests that the presence of mDia2 in the
nucleus is important for its effects on MRTF activity.  Since the binding of MRTF
to G-actin in the nucleus enhances MRTF nuclear export, we hypothesize that
mDia2-mediated actin polymerization in this compartment is a critical mechanism
that regulates MRTF nuclear localization. Although FHOD1 localization was not
affected by Crm-1-dependent shuttling, a previous study has demonstrated that a
catalytically active caspase cleavage fragment of FHOD1 (the C-terminal 2/3 of
the molecule) localized to the nucleus suggesting that FHOD1 may also have a
nuclear role.
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The goals of the present study were to evaluate the contributions of
FHOD1 to SMC-specific gene expression and to test whether phosphorylation
and/or nuclear localization play important roles in regulating FHOD1 activity.
Materials and Methods
Plasmids and FHOD1 mutations
FHOD1 mutations (see Figure 4.4A) were generated using the
QuikChange mutagenesis kit (Stratagene). All FHOD1 constructs were
subcloned into flag-tagged pcDNA3.1 for mammalian expression or pGEX-4T1
(Amersham) for the generation of GST-fusions. Please see supplemental
methods for more detailed protocols.
Cell culture, transfections, and promoter assays
Multipotential 10T1/2 cells and primary rat aortic SMC cell cultures,
transient transfections, and promoter luciferase assays have been previously
described (103). Statistical comparisons between groups were made using the 2-
tailed Student's t test with statistical significance accepted at p<0.05.
Antibodies, immunoblots, and immunoflourescence
GFP-FHOD1 and the FHOD1 antibody were generous gifts from Michael
Mendelsohn (Tufts University, Boston, Mass.).  Rat tissue extracts were prepared
as previously described (69).  Immunoflourescence was performed as previously
described (189).  Cells were treated with 0.5µM Latrunculin B for 8 hours prior to
fixation.
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Results
FHOD1 can regulate SM-specific transcription in an actin-dependent manner
Because FHOD1 is expressed in SMC and can stimulate actin
polymerization, we hypothesized that it, like mDia1 and mDia2, plays a role in
regulating SMC-specific transcription.  To begin to test this we co-transfected
FHOD1 into multipotential 10T1/2 cells along with SM α -actin and SM22
promoter-luciferase constructs.  As shown in figure 4.1 addition of full-length (FL)
FHOD1 stimulated both SM α-actin and SM22 promoter activity by a relatively
modest 2-fold (Figure 4.1A). However, expression of a constitutively active
FHOD1 variant that lacks the N-terminal DID domain activated the SM α-actin
and SM22 promoters by 54 and 23-fold, respectively. Importantly, 0.5µM
treatment for 8hrs with the actin polymerization inhibitor, Latrunculin B,
dramatically inhibited the effects of CA FHOD1-induced on SM α-actin and SM22
promoter activity.  These results clearly suggest that FHOD1 can regulate SMC-
specific transcription in an actin polymerization-dependent manner.
To determine whether endogenous FHOD1 regulates SMC-specific gene
expression in our model, we knocked down FHOD1 expression using an RNAi
sequence published by Takeya et. al. (194). As shown in figure 4.1B, we
achieved FHOD1 knockdown in 10T1/2 cells using 150nM RNAi (compared to
non-targeted control RNAi), which was accompanied by a 70% decrease in SM
α-actin protein expression.  This establishes the requirement of FHOD1 in SM α-
actin expression in the 10T1/2 precursor cell model.
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CA FHOD1 activates MRTF-B
Another mechanism of FHOD1-dependent increases of SMC-specific
transcription is activation of MRTF-B.  Over-expression of MRTF-B in 10T1/2
cells results in a modest increase in SM α-actin promoter activity of 2 fold over
the empty vector alone (Figure 4.2A).  With wild type FHOD1, the MRTF-B is still
only 4 fold over the empty vector.  CA FHOD1 alone-induced promoter activity
was a respectable 44 fold relative to empty vector.  However, the addition of CA
FHOD1 and MRTF-B is 2.5 times greater than that, with a 116 fold increase over
empty vector.  This is also 30 times greater than the MRTF-B condition
containing the inactive FHOD1.  Clearly, activated FHOD1 potently stimulates
MRTF-B-dependent promoter activity.
MRTF-B resides in the cytoplasm in unstimulated cells.  Consistent with
the promoter activation, addition of full-length, wild type FHOD1 does not change
this localization.  However, in the presence of CA FHOD1 dramatically drives
MRTF-B to the nucleus (Figure 4.2B).  Thus, the underlying mechanism of
FHOD1 regulation of MRTF-B must involve its nuclear translocation.
DAD phosphorylation enhances FHOD1-mediated SMC-specific transcription
Takeya et. al. have shown that the FHOD1 DAD is phosphorylated at
S1131, S1137, and T1141 by Rho-kinase (194). Additional data from these
studies as well as from our lab suggest that phosphorylation of residues within
the DAD domain enhance DRF activity. To test whether FHOD1 phosphorylation
enhances SMC-specific promoter activity, we made phosphomimetic mutations
to these DAD residues (Fig.4.3). We found that the phosphomimetic  mutations
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 significantly increased FHOD1-mediated SMC-specific promoter activity (see
Figure 4.3A). Although, we believe that these mutations enhance FHOD1 by
interfering with the DID-DAD interaction, it is also possible that these mutations
could have increased FHOD1's catalytic activity. To test this directly, we made
the same mutations in the CA variant of FHOD1. As shown in figure 4.3A,
phosphomimetic mutations in this context did not increase FHOD1 activity (if
anything they had negative effects on FHOD1 activity). Taken together these
results suggest that phosphorylation at these residues appears to play a role in
the activation of SMC-specific transcription by FHOD1.
Does FHOD1 function in the nucleus?
Recent work by Vartiainen et. al. has shown that nuclear G-actin inhibits
MRTF transcription by enhancing Crm-1-dependent MRTF nuclear export and
perhaps by inhibiting transcription initiation complex formation (198).  Our
previous studies suggest that mDia2 shuttles through the nucleus and may have
important effects on MRTF activity by regulating nuclear actin polymerization.
Based upon a previous study demonstrating that an FHOD1 caspase cleavage
fragment localizes to the nucleus, we hypothesized that FHOD1 may also have a
nuclear function.
As a first step in examining this hypothesis we generated a series of flag-
tagged FHOD1 deletion constructs (Figure 4.4A) whose localization was
analyzed by immunohistochemistry.  As shown in Figure 4.4B, full-length wild
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type FHOD1 is expressed in the cytoplasm.  Deletion the N-terminus (as in the
CA FHOD1 construct) results in nuclear localization of FHOD1, suggesting a
component of the N-terminus may be stimulating its cytoplasmic localization.
Additionally, expression of the FHOD1 variant that is lacking the DAD (lacking a
piece of the C-terminus), FHOD1 ΔDAD, results in cytoplasmic localization of
FHOD1.  This suggests that a component of the DAD stimulates FHOD1 nuclear
localization.  These data suggest that the DAD domain contains an NLS and that
the C-terminal DID domain may also contain a nuclear export signal (NES).
Construction of more variants may be required to identify the exact NLS and
NES.
The observations that CA FHOD1 could strongly activate SMC-specific
transcription and localized predominantly to the nucleus support our idea that
DRF function in the nucleus may be important for MRTF activity and SMC-
specific transcription. To test this further, we co-transfected several of the
FHOD1 localization variants into 10T1/2 cells along with SMC-specific promoter
luciferase constructs.  Importantly, the CA FHOD1 variant lacking the DAD
domain (CA ΔDAD) which exhibited mainly diffuse or cytoplasmic localization
could not activate the SM α-actin promoter as strongly as CA FHOD1.  In
addition, although removal of the DAD from full length FHOD1 (FHOD1ΔDAD)
also results in constitutive FHOD1 activity, this variant had much less of an effect
on SMC-specific promoter activity than CA FHOD1. These data indicate that
nuclear localization of FHOD1 may be important for its effects on SMC-specific
96
97
transcription and support a closer examination of the mechanisms that regulate
this process.
The phosphomimetic DAD mutations inhibit FHOD1 nuclear localization
Our FHOD1 deletion series suggested the presence of a NLS within the
N-terminal DAD region. Interestingly, this domain contains many basic residues
including the basic region that was shown to be important for the DID-DAD
interaction that could function in this capacity.  Although we have not completely
identified the NLS within this region, we hypothesized that phosphorylation of the
three S/T residues within the DAD would inhibit this NLS activity by disrupting the
positively charged nature of this domain. As shown in figure 4.4D, the addition of
a single phosphomimetic residue (S1131E) significantly inhibited the nuclear
localization of both CA FHOD1 and the FHOD1 DAD.  It is important to note that
these effects were certainly not complete even in FHOD1 variants containing the
triple phosphomimetic mutation.  Thus, although these mutations slightly reduced
CA FHOD1's effects on SMC-specific promoter activity (Figure 4.3A), it is difficult
to conclude whether this mechanism significantly regulates FHOD1 function in
this context.
Discussion
ROCK activation of FHOD1 provides this pathway with physiological
relevance.  ROCK responds to thrombin, lysophosphatidic acid, and other G-
protein coupled receptors to stimulate an increase in stress fiber formation (115).
This occurs through activation of LIM kinase and subsequent phosphorylation
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and inactivation of the actin depolymerizing protein cofilin (115).  Stress fiber
formation also occurs through phosphorylation and inactivation of myosin light
chain phosphatase (24).  Evidence from Staus et al (190) now indicated ROCK-
dependent phosphorylation in the activation of mDia2 and evidence from Takeya
et. al has identified FHOD1 as an additional substrate and actin polymerizing
factor (194).  The DRFs were initially identified in mammals as a profilin binding
protein (207), which further supports a physiological role for FHOD1 in stress
fiber formation.  The Dia GTPase binding domain (GBD) binds Rho-GTP, and
activates the actin nucleating capabilities of the FH2 domain (169).  The DRFs
have individualized specificity for Rho GTPases, which results in the hypothesis
that they also have individualized function. (44, 209) (85, 112).  However, there is
much room for clarification of their individualized function.
FHOD1 specificity for SMC genes
FHOD1 is expressed in both aortic and coronary human SMCs (204), and
data in this paper has identified that FHOD1 has a regulatory role in SMC-
specific gene expression.  FHOD1 induced promoter activity was initially tested
using the pSRE (209).  The pSRE was described in 1986 by (196) as the
responsive element for growth response genes, such as c-fos and egr-1.  SRF
was then identified as the activating factor for these promoters (195).  SRF has
since been identified as a required component of nearly all SM-specific genes
(96, 109, 113, 130) and FHOD1-dependent activation of these genes may also
have some specificity.  The knock-down of FHOD1 in 10T1/2 cells would also be
useful for expression analysis including other SMC-specific proteins.  I have also
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shown that knock-down continues after splitting the cells, which would allow
promoter assays using cells with decreased FHOD1 expression.  Finally, the
FHOD1 expression profile in mouse tissue could be analyzed using the
previously described FHOD1 antibody (204).
Alternative nuclear export
Although mDia2 nuclear export is achieved via a Crm-dependent
mechanism, FHOD1 nuclear export was not inhibited by the Crm inhibitor
Leptomycin B (189).  Deletion mutants in figure 4.4 suggest that FHOD1 contains
an NLS in the C-terminal DAD and an NES in the N-terminal DID.  If more of the
N-terminus is added back to the CA construct the protein becomes cytoplasmic
again (data not shown), suggesting that an NES may exist in the N-terminal DAD
domain. (between amino acids 135 and 492).  Although other nuclear export-
mediating proteins are known, identification tools are not as well developed.
These proteins include exportin (4,6, or 7), importin 13, or CAS.  Of possible
interest, both profilin and actin nuclear export is mediated by exportin 6 (156). In
order to determine whether FHOD1 export is regulated, mutations should be
targeted between FHOD1 amino acids 135 and 492.  Once the putative NLS and
NES domains have narrowed, chimeric proteins could be used to determine the
strength of the signal.  These chimeras would be designed to answer whether the
proposed NLS can drive a normally cytoplasmic protein to the nucleus and
whether the proposed NES can drive a normally nuclear protein to the cytoplasm.
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Does CA FHOD1 exist endogenously
Given that the CA FHOD1 is a truncated version of the protein, it is
possible that it exists as an endogenously expressed protein. Interestingly,
FHOD1 has a caspase cleavage site at SVPD 616 that leaves a protein similar to
our CA FHOD1 (129).  Alternatively, does the full-length FHOD1 have a nuclear
function?
Nuclear actin dynamics have recently been identified as an important
regulator of MRTF-A (human isoform, MAL) -induced promoter activity (198).
MRTF-A rapidly shuttles between the cytoplasm and the nucleus and binds
monomeric actin.  Fluoresence resonance energy transfer was used to
demonstrate the interaction of MRTF-A with globular actin in the nucleus (198).
Fluorescence recovery after photobleaching (FRAP) can also be used to identify
nuclear shuttling of a protein into the nucleus.  This technique may be useful for
studying nuclear targeting of FHOD1 to determine whether its nuclear function
and localization is physiological and this is a technique that is currently being
perfected in the lab.
In summary, FHOD1 contributes an additional mechanism of regulating
SMC-specific expression.  These studies outline the groundwork, although there
is still much necessary work to clarify its role as a SMC-specific genetic program
activator and a potential nuclear actin polymerizing factor.
CHAPTER V
Conclusions and Future Directions
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Conclusions and Future Directions
VSMCs participate in vascular diseases by changing their phenotype and
migrating toward the lumen of a vessel, which can be protective as well as
destructive.  Questions arose as to not only how are SMCs specified, but also,
how could we force SMCs to maintain a balance in their phenotype that
minimizes risk of vascular occlusion?  When work for this thesis was started,
understanding of the regulation of the VSMC phenotype had begun to address
how a ubiquitously expressed transcription factor, SRF, could mediate the
expression of immediate early and growth genes as well as genes that are
specific for all three myogenic lineages.  With the identification of the myocardin
family of transcription factors, some of the mystery subsided.  There are yet
additional regulatory mechanisms, including SRF post-translational modifications,
RhoA signaling, and actin-mediated responses.  Although SRF was identified as
a phosphoprotein many years ago (62, 119, 123), the significance of this finding
was not initially appreciated because of its low effect on SRF promoter targets
being studied at the time. However, in SMCs, the SMC-specific promoters have a
lower affinity for SRF, which makes them more susceptible to changes in SRF.
SMCs are the only myogenic lineage that does not terminally differentiate.
SMCs require a dynamic equilibrium of SMC-specific versus proliferative gene
expression profiles and the regulation of this equilibrium is a key component in
the participation of VSMCs in injured vessel repair and disease.  Therefore, the
focus of this thesis was identifying a dynamic regulatory event in SRF that could
mediate this transition.
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The studies presented in this thesis contribute to the knowledge of the
regulation of SMC-specific phenotype by identifying a pathway of PKA-
dependent regulation of SRF activity, exploring the possibility of SUMO
regulation of SRF activity, and by identifying a role for a novel regulator of the
VSMC phenotype, FHOD1.
SRF MADS domain phosphorylation
In chapter II, “PKA-Dependent Phosphorylation of Serum Response
Factor Inhibits Smooth Muscle-Specific Gene Expression,” I have identified a key
phosphorylation site in the MADS domain, T159, that inhibits SMC-specific
expression, while still allowing expression of c-fos.  SRF is phosphorylated by
PKA in a mechanism that inhibits SRF-dependent SMC-specific transcription.
PKA is a known regulator of SMC-specific expression and it exerts additional
regulatory forces on SMCs by inhibiting RhoA signaling (71, 143). Thus, its
negative regulation of SRF is a fitting contribution.  In PKA stimulated cells,
variations in SMC-specific promoter affinity for SRF allow SM22 –but not SM α-
actin –promoter activity to be rescued by myocardin.  However, the exact
differences in the sequences flanking the CArG elements that may affect whether
the cofactors can rescue binding have not been identified.  In order to confirm
whether the CArG sequences themselves are responsible for the variability in
affinity or the sequences flanking the CArG elements, probes that are chimeras
of two different promoters would be used.  For example, the SM α-actin intronic
CArG could be used in the context of the SM22 Far flanking sequences, with the
hypothesis that SRF T159D plus myocardin will form the higher order complex
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with the chimeric probe.  If this is true, then additional mutations could be
engineered to identify the sequence that is interacting with myocardin.
There are many reports of SRF phospho-residues, however, their
existence in VSMCs has been less studied. One approach for understanding
modifications of SRF that may be important in VSMCs is analysis by mass
spectrometry.  The VSMCs would be treated with different agonists, such as PKA
agonists, TGFβ, and PDGF-BB.  Purified SRF would be submitted to identify
phosphorylation sites under different stimuli.  Most of the historical SRF
phosphorylation studies were performed without the context of the VSMC, so this
experiment may give some direction as to which of the many previously identified
sites actually occur in SMCs.  Additionally, it would describe the phenotypic
context of the cells at the time of the phosphorylation.  The identified sites could
then be pursued as potential regulation sites of SMC-specific expression.
When phospho-residues of importance, such as T159 or the published
S162 (79) are identified, the mutations could be used to make a mutant mouse to
determine whether these sites are required for VSMC expression in an animal or
whether compensatory mechanisms will apply.  Current data by Iyer et. al. have
asserted that growth genes having cofactors with their own promoter binding site
(ex. Elk1) can overcome the SRF S162 phosphorylation-dependent inhibition of
CArG binding (79).  Therefore, in a global replacement by homologous
recombination of the SRF locus with SRF S162E or SRF T159D, we would
hypothesize that the mouse phenotype would be embryonic lethal at the time of
cardiovascular dependency (between E9 and E11.5).  The SRF phosphorylation
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mimetic genetic replacement animals should complete gastrulation (a
complication in the SRF -/- mice), and will most likely suffer from contractile
defects similar to the cardiovascular-specific, SM22α-Cre SRF deletion mouse.
Regulation of SMC phenotype by PKA
Inhibition of SRF-dependent SMC-specific expression by PKA
phosphorylation is in concert with known PKA regulation of SMCs.  However,
signaling by PKA is complex as it functions through multiple pathways, affecting
contraction and relaxation, proliferation and migration, and expression of SMC-
specific genes.
SMC contraction and relaxation is key in maintaining a functional vessel
and the complete mechanism by which PKA contributes to this dynamic is still a
focus of research.  It has been suggested that cAMP-dependent relaxation (160)
of arterial SMC most likely occurs through PKA (159).  One possible mechanism
of relaxation occurs as PKA phosphorylates myosin light-chain kinase (MLCK).
During contraction the calcium-calmodulin complex binds and activates MLCK,
resulting in MLCK phosphorylation and activation of myosin and contraction of
the SMC. The PKA-induced relaxation is proposed to occur by phosphorylating
MLCK and thereby reducing its affinity with the calcium-calmodulin complex
(185).  Relaxation can also be achieved by myosin light chain phosphatase-
induced de-phosphorylation of myosin.  PKA phosphorylation of telokin enhances
myosin light-chain phosphatase activity, thereby activating another mechanism of
relaxation (215).  Finally, levels of intracellular free calcium are regulated by
receptors on the sarcoplasmic reticulum.  Inositol 1,4,5-triphosphate receptors
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move intracellular calcium into sarcoplasmic internal stores.  PKA
phosphorylation of these receptors and/or phospholambin facilitates the
sarcoplasmic reticulum uptake of free calcium (92, 212).  Thus, PKA has a multi-
faceted role in the regulation of SMC relaxation.
SMC proliferation and migration is also regulated by PKA activity.  PKA
inhibits of proliferation and migration through interfering with many growth factor-
dependent pathways in SMCs (reviewed in (10)).  Near the cell membrane the
inhibition can occur at many levels, including inhibition of Ras-Raf-MAPKK
pathway, phosphatidylinositol 3-kinase, and mTOR.  In the nucleus inhibition is
through cyclin/cdk complexes, and other gene responses, such as protein
translation (10).  Specifically, in prostate SMCs activation of PKA inhibited
lysophosphatidic acid (LPA)-induced SMC proliferation (2). A similar result was
observed in ovarian cancer cells, where activation of PKA inhibited LPA-induced
proliferation and c-fos promoter activity.  These researchers also identified a
decrease in stress fibers and a decrease in focal adhesion by paxillin, both
important components of migration (143).  Additionally, LPA-induced migration of
airway SMCs was inhibited by PKA (70).
One mechanism of PKA-dependent regulation of stress fiber formation is
phosphorylation of RhoA (37).  PKA phosphorylates RhoA at S188, which results
in an increased association of RhoA with Rho-guanine-dissociation inhibitor.
Mutation of RhoA-S188 protected RhoA from the stress fiber disassembly that is
induced by activating PKA (37).  This clarifies one role of PKA-dependent
inhibition of SMC function.
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RhoA-dependent actin polymerization also stimulates SMC-specific
expression (110).   The mechanism of activation involves an actin polymerizing-
dependent nuclear localization of the SRF cofactors MRTF-A and MRTF-B (69).
The contribution of this thesis is a novel PKA phosphorylation event in the
SRF MADS DNA binding domain at T159.  Phosphorylation of SRF T159 inhibits
SRF-dependent SMC-specific transcription.  Importantly, this inhibition can be
rescued to an extent by the myocardin family of transcription factors by stabilizing
interaction with the SM22 promoter, but not the SM α-actin promoter.  Previous
work by Iyer et. al. determined that phosphorylation at a neighboring SRF site,
S162, could not be rescued by the myocardin cofactors in the case of cardiac- or
SM α-actin promoters (79).  However, in the case of the c-fos promoter
phosphorylation of the critical SRF S162 residue can be rescued by the co-
expression of the growth gene cofactor, Elk1.  The growth gene ternary complex
cofactors, such as Elk1, bind DNA directly and thus stabilize the SRF interaction
with DNA (79). As the SM α-actin promoter activity or binding could not be
rescued in either the SRF T159 or S162 phosphomimetics, SRF MADS
phosphorylation and regulation of the SMC phenotype may be more important for
down regulating the SMC contractile-specific genetic program.  As described,
myogenic or growth gene cofactors participate in the overall outcome of the SMC
phenotype.  Therefore PKA signaling may inhibit either program depending on
additional signaling in the SMC.
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Sumoylation projects
In chapter III, “Potential Regulation of SRF-Dependent Gene Expression
by SRF Sumoylation,” I explored sumoylation of SRF as a post-translational
modification that could regulate its activity.  Sumoylation may regulate SRF
function, although there is no conclusive evidence that this occurs in SMCs.
After confirming the SRF interaction with Ubc9 and identifying an in vitro target,
subsequent data using the SUMO-defective SRF K147R showed no affect on
SMC-specific promoter activity, promoter binding, or differentiation in the
differentiation assay.  Initial complications with this project arose from both not
identifying the stimulus or conditions in which SRF might be sumoylated and not
having a “SUMO-SRF” mimetic.  SUMO is covalently added as a side chain to
target proteins and adding SUMO the N- or C-terminus of a protein is far from
physiological.  Therefore, SUMO-defective mutants were the primary tool and
there was essentially no difference between these mutants and the wild type
SRF-induced promoter activities.  We can hypothesize that this is a result of the
physiological conditions of the cells in culture not supporting a sumoylated SRF
state.
Sentrin-specific proteases (SENP) are enzymes that deconjugate SUMO
from the substrate protein.  We obtained SENP1 from Gong et. al. (49) and if this
project were pursued it could be used to confirm that a potential higher molecular
weight protein is sumoylated SRF.  Co-expression of SENP1 would remove the
SUMO protein and leave the typical 67kDa SRF protein.  These assays could be
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performed under various SMC agonists, as described for the endogenous
phosphorylation studies.
If SRF is sumoylated in vivo, one function could be protecting SRF from
degradation.  This hypothesis could be tested by treating cells with a proteosome
inhibitor to determine whether this results in an increase in the presence of SRF
protein.  If this occurs, then the recognition motif surrounding the target lysine
residue should be mutated rather than the lysine itself.  This is because if the
degradation were occurring by ubiquitination, the ubiquitin could be added to the
same lysine that may get sumoylated instead.  The primary difference being that
such a recognition motif has not been identified for ubiquitination. Therefore, if
we mutate the recognition sequence and then degradation occurs, then
sumoylation could provide a protective function by preventing ubiquitination at
the same residue.  Additonally, if the function of sumoylation is to prevent
ubiquitination, then the current SUMO-defective SRF mutants that have mutated
lysine residues would not need SUMO to protect them because they cannot be
ubiquitinated at this site now anyway.
Another possibility is that the Ubc9 identified in the yeast-2-hybrid screen
and the confirmed interaction was secondary to SRF interacting with proteins that
are sumoylated.  There is a report of the human isoform of MRTF-A, MAL, being
sumoylated (139).  Also, the E3 enzyme of sumoylation, Pias1, interacts with
class I basic helix-loop-helix proteins to regulate SMC-specific transcription in a
mechanism that is independent of its ligase function (83).
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FHOD1 project
Based upon previous studies in our lab demonstrating the importance of
actin polymerization as a regulator of SMC-specific gene expression (189) the
goal of chapter IV, “FHOD1 Regulates VSMC-Specific Gene Expression,” was to
examine the role of the diaphanous related formin, formin-homology-domain-
containing protein 1 (FHOD1) in this process.  My studies were the first to
demonstrate that FHOD1 regulates SMC-specific gene expression by stimulating
activity of the MRTF-B cofactor in an actin polymerizing-dependent manner.
However, the extent of the FHOD1 function is still unclear.  Previous work has
shown that knockdown of FHOD1 results in a significant decrease in actin
polymerization (194).  In the cytoplasm, we know that FHOD1 increases actin
polymerization and previous work from our lab and others has shown that actin
polymerization increases nuclear localization of MRTF-A and MRTF-B (69, 103).
In regards to this project, the remaining question is whether FHOD1 has
an endogenous nuclear function.  Work in this thesis has shown that deletions in
FHOD1 result in its nuclear localization.  However, further deletions and
mutations of the putative NLS and NES are necessary to clarify the specific sites.
Another method of confirming an NLS or NES is making a chimeric protein.  The
chimera should include a protein that is known to reside in the opposing location
of the signal, with the hypothesis that the proposed NLS or NES will drive the
protein to the nuclear or cytoplasmic compartment, respectively.
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Role of actin dynamics in the nucleus
The first implications for nuclear actin in the regulation of transcription
occurred in 1984 (36, 173), although its nuclear presence was debated for much
longer (91).  The existence of actin in the nucleus is now certain with new
microscopic technology (126) and with the identification of a specific nuclear
actin export receptor (192).  Actin dynamics and interactions with nuclear
complexes provide an exciting, relatively new field of potential transcriptional
regulation.  The complete function of actin in the nucleus is unknown, although
there are implications for a role in gene expression, transcription factor regulation
and intranuclear motility.
The form actin takes in the nucleus is somewhat unknown.  Typical
microscopy techniques (ie. phalloidin staining) are not sensitive enough for
nuclear filaments due to their low concentration relative to cytoplasm filaments,
their potentially shorter and not bundled fibers, and their covering by other
proteins (197). There has been debate over whether actin forms filaments in the
nucleus until recent work by McDonald et. al. (126).  Using fluorescence recovery
after photobleaching (FRAP), it was determined that 20% of nuclear actin exists
as filamentous actin and their work showed turnover rates that were slightly
higher than cytoplasmic actin.  However, the diffusion of a monomeric molecule
through the nucleoplasm is at least 50 times slower than expected (126).  These
data indicate that nuclear actin may have a function that varies from that of the
cytoplasm.
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Nuclear actin participates in transcription through chromatin dynamics and
through direct interaction with polymerases.  Chromatin is regulated by many
epigenetic factors and nucleosome remodeling and modifications are key in
regulating gene expression (7).  The multi-subunit human SWI/SNF chromatin
remodeling complex, BAF, was purified with β-actin bound to the ATPase Brg1
subunit so tightly that it cannot be separated without denaturing Brg1 (235).
Actin was subsequently found in complex with additional chromatin remodeling
complexes of Drosophila, yeast, and human -which some contain histone
acetylase and others deacetylase activity (see (150) for review).
Actin is also a component of at least three common RNA polymerases
(157).  The phosphorylated c-terminus of RNA polymerase II binds both
heterogeneous ribonucleoprotein U (hnRNP U) and actin directly.   The
interaction stimulates transcription of most of the RNA polymerase II gene targets
(87).  One explanation of RNA polymerase II activation is the possible
recruitment of a histone acetyltransferase, as hnRNP U also binds p300/CBP
(124).  RNA polymerase II has also been identified in complex with actin and
neuronal Wiskott-Aldrich syndrome protein (N-WASP).  N-WASP is a key
regulator of actin filaments and this interaction suggests that mediation of nuclear
actin filaments may participate in transcriptional regulation (216).
As actin has many binding partners and is incorporated in the regulation of
many epigenetic factors it has been proposed that it may serve as a molecular
platform for the recruitment of modifying enzymes (157).  Additionally,
mammalian chromatin is non-randomly organized into distinct chromosome
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territories (7).  The organization of the compartments may depend on nuclear
actin for architecture.  Under this model the activation of a gene may require
movement of entire regions of chromatin and actin through actin dynamics that
may function quite differently than in the cytoplasm.
Recent work by Vartiainen et. al. shows actin dynamics in the nucleus
regulate myocardin factor/SRF activation with equal strength of cytoplasmic actin
dynamics (198).  Even when trapped in the nucleus, myocardin factor
transactivation is inhibited by interactions with globular actin (198).  Importantly,
MRTF-A (MAL) still forms a complex with SRF, as shown by chromatin
immunoprecipitation, however, if actin is not polymerized then the MRTF-A/SRF
complex is inactive.  This suggests that the globular actin (g-actin)-induced
inhibition of MRTF-A is due to an inhibition of interactions with the transcription
complex.  The second proposed explanation is that as g-actin interacts with the
SWI/SNF complex, the globular actin-bound MRTF-A is also associated with the
complex.  However, since MRTF-A has not been found in complex with
SWI/SNF, the first explanation is more accepted(214).  In either circumstance,
the exact mechanism of g-actin function is not clear and a DRF contribution to
either pathway would be exciting.
The DRFs may participate in the regulation of actin polymerization in the
nucleus (191) in a mechanism that compliments results found by Vartiainen et.
al. (198).  In results presented here I determined that inhibition of actin
polymerization by latrunculin B also inhibited promoter activity induced by CA
FHOD1.  Additionally, CA FHOD1 is expressed in the nucleus and also
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stimulated nuclear translocation of MRTF-B.  Thus, a nuclear function for DRFs
similar to their role in the cytoplasm is feasible, although whether endogenous
FHOD1 is targeted to the nucleus is unknown.  There is one report showing a
SVPD caspase cleavage site in FHOD1 at amino acid 616, although the context
of the paper is apoptosis (129).  However, if caspases have a basal level of
activity, then this is one possible mechanism of endogenous FHOD1 nuclear
targeting.
Although cytoplasmic FHOD1 has defined functional importance, whether
endogenous FHOD1 expresses in the nucleus is a very interesting unanswered
question.  Fluorescent recovery after photobleaching (FRAP) is a useful tool for
showing the entrance of a protein into the nucleus, which may be key in
understanding the contribution of FHOD1 to regulation of actin dynamics and
SMC-specific expression.  In FRAP a light source of high intensity illumination of
the appropriate wavelength is focused to a small patch of fluorophores and
causes their fluorescence lifetime to elapse.  Then the entrance of new
fluorescently-tagged proteins to the area can be measured. This technology
could be used to answer multiple questions including whether CA FHOD1 is
activating nuclear actin polymerization as well as cytoplasmic (using GFP-actin)
or whether the FL FHOD1 is targeted to the nucleus when activated (using GFP-
FL FHOD1).  This is an exciting direction that the Mack lab is pursuing.
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SMC phenotypic regulation
In combination, these data support two different aspects of SMC
phenotype regulation.  Regulation by PKA inhibits SMC-specific SRF-dependent
expression and allows activation of genes expressed during the “synthetic”
phenotype.  FHOD1 activation stimulates actin polymerization, MRTF-dependent
SRF activation, and may have a nuclear function.  In a state of vascular disease,
both phenotypic states are necessary.  At the site of injury SMC proliferation and
migration must occur to stabilize the vessel wall, which must be followed by the
SMC contractile phenotype if the vessel is to reach a healthy function.
In hypertrophied vessels, vascular stents are often surgically inserted to
prevent vascular occlusion.  However, SMCs often proliferate and migrate
through the mesh stent.  A clinical focus for many years has been identifying an
appropriate compound to coat the stent and stimulate a contractile SMC
phenotype rather than the proliferative phenotype (230).  In pursuit of such a
polymer, regulation of SMC phenotype by either PKA-dependent SRF
phosphorylation or FHOD1-dependent SMC-specific expression could be used
as potential drug targets.  Since PKA inhibits SMC-specific transcription but also
regulates SMCs by different mechanisms, the SMC contractile phenotype could
be stimulated by delivery of small doses of a compound designed to serve as a
surrogate PKA consensus binding site in the nucleus.  This should decrease PKA
phosphorylation of SRF without inhibiting other functions of PKA in the cell.
FHOD1 could be transiently activated by time-released delivery of a compound
that interferes with the DID-DAD interaction, thus relieving the negative
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interaction and stimulating SMC-specific transcription.  Either of these proposed
pathways should not entirely interfere with the proliferative genetic program, but
would rather stimulate the contractile phenotype and result in a functional vessel.
Cardiovasular research has many potential clinical applications, which makes it
an exciting area of continuous research.
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